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Abstract 
 
Brian M. Kile: The Study of Dopamine Dynamics in Transgenic Mouse Models 
(Under the direction of Dr. R. Mark Wightman) 
 
Brain slice experiments are a robust and controlled platform for the study of neurotransmitter 
dynamics using electrochemistry.  The isolation and study of brain slices from genetically 
altered animals is critical for the understanding of neurotransmitter dynamics.  The dynamics 
of biogenic amine neurotransmitters are important for movement and addiction studies.  This 
dissertation focuses on the use of five separate transgenic mouse models to increase the 
understanding of biogenic amine transmission in the brain.  Fast scan cyclic voltammetry 
and amperometry at carbon fiber microelectrodes were used to directly monitor the 
dynamics of dopamine, serotonin, and norepinephrine.  The amount of neurotransmitter 
available to act on neuronal targets is a balance of release and uptake.  A transgenic mouse 
model lacking the presynaptic protein synapsin was used to show that dopamine has a 
unique presynaptic architecture making it susceptible to release facilitation by cocaine, a 
drug of abuse.  Additionally, mice expressing different amounts of the dopamine transporter 
were studied to show that the dopamine transporter is a critical regulator of extracellular 
dopamine concentrations.  The importance of mitochondrial energy output was studied in 
animals lacking uncoupling protein 2, a regulator of mitochondrial function and two disease 
state mouse models indicated a relationship between obesity and dopamine release that 
does not extend to mental retardation.  High performance liquid chromatography was used 
to support the conclusions drawn from the electrochemical measurements in brain tissue.  
Finally, methodologies related to brain slice experimentation were evaluated to better 
understand how these measurements can be improved. 
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Chapter 1 
Analytical Neuroscience and Transgenic Animals 
 
Introduction 
Information is transmitted through the brain via electrical impulses carried along 
neurons, specialized cells capable of propagating electrical and chemical signals (Figure 
1.1).  Electrical signals are carried along the dendrites and axon of the neuron by ion 
movement (primarily Na+, K+, and Cl-) across the plasma membrane (Hodgkin and Huxley, 
1952a, b).  The ion gradient that is created due to this movement changes the relative 
potential of the plasma membrane.  Wave like potential changes along the plasma 
membrane allow for information to pass along the axon, dendrites, and cell body (Figure 
1.2).  The normal resting potential of a neuron is negative; positive deflections in membrane 
potential are considered excitatory while negative changes are considered inhibitory.  A 
neuron will receive excitatory and inhibitory electrical inputs at its dendrites where they will 
be summated at the cell body.  If the summated inputs exceed a predetermined threshold, 
the cell will fire an action potential that propagates down its axon.  The axon synapses with 
the dendrites of target neurons at which point electrical propagation of the signal switches to 
a chemical form of communication.  Information is transmitted at synapses through the use 
of chemical messengers termed neurotransmitters.  When the action potential reaches the 
synapse, voltage gated Ca2+ channels open and Ca2+ enters the presynaptic terminal.  The 
influx of Ca2+ triggers exocytosis, the fusion of intracellular vesicles with the plasma 
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Figure 1.1  A schematic of a unipolar neuron depicting the major structures associated with 
this cell type.  Electrical inputs (both excitatory and inhibitory) are received at the dendrites, 
summated at the cell body, and propagated down the axon to target neurons.  Some 
neurons have a myelin sheath around their axons helping to propagate axon potentials more 
quickly (biogenic amine neurons do not).  The axon branches forming multiple synapses 
(the site of neurotransmitter release) with target neurons.  This figure has been modified 
from a similar illustration found at www.drugabuse.gov. 
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membrane followed by the expulsion of neurotransmitters into the extracellular space.  
These chemicals diffuse to pre- and postsynaptic targets where they trigger responses via 
specific receptors. 
The action of neurotransmitters at their targets depends upon the location of 
synapse, the type of neurotransmitter, and the type of receptor that it binds.  In general, 
neurotransmitters will act either to open an ion channel, affecting the polarity of the 
postsynaptic cell, or to begin an intracellular messenger cascade, changing how the target 
cell operates on a longer time scale (Brown and Birnbaumer, 1989; Unwin, 1993).  The 
duration of action for most neurotransmitters is short; therefore, clearance mechanisms exist 
to cease neurotransmitter action.  These include uptake into neurons by membrane bound 
transport proteins, a relatively rapid process, and the slower process of degradation by free-
floating enzymes in the extracellular space (Kandel, 2008). 
 The biogenic amine neurotransmitters primarily act as modulators of neuronal activity 
in the brain.  The biogenic amines include serotonin (5-HT), dopamine, and norepinephrine 
(NE).  These chemicals are known to modulate movement, wakefulness, mood, pleasure, 
addiction, and appetite (Cooper et al., 2003).  Proper understanding of neuronal function 
related to these neurotransmitters has implications for disease state and addiction studies.  
An example of the ability of these neurotransmitters to modulate behavior is the 5-HT 
modulation of dopamine release (Fink and Gothert, 2007).  Selective antagonism of 5-HT2A 
receptors can alleviate movement phenotypes commonly associated with 
hyperdopaminergia (Barr et al., 2004).  5-HT innervation of the dopamine cell bodies in the 
midbrain changes their firing rate which affects the amount of dopamine released in the 
striatum.  In the striatum, dopamine is responsible for modulation of the synaptic strength 
between γ-aminobutyric acid (GABA) (the main inhibitory neurotransmitter) neurons and 
glutamate (the main excitatory neurotransmitter) neurons (Chase and Oh, 2000).  Released 
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dopamine acts on the glutamate-sensitive medium spiny neurons (GABAergic neurons that 
project to motor cortex) altering the ability of released glutamate to initiate movement.  This 
example demonstrates how biogenic amines can regulate each other as well as other 
neurotransmitters and how this regulation relates to behavioral responses.   
Murine Brain Slices 
 Neurons exist in tightly packed networks that weave throughout the brain to different 
targets of action.  In many cases the neurotransmitter target is distal to the location of the 
cell bodies.  A cluster of cell bodies, known as a nucleus, will project a bundle, or tract, of 
axons to multiple sites of termination.  This organization can be seen in the serotonergic 
system where three cell nuclei are responsible for distributing 5-HT to 17 different target 
regions (Heimer, 1995).  Dissection of live tissue by techniques such as the preparation of 
brain slices facilitates the isolation of these systems for study.  Isolation can involve the 
selection of a specific neurotransmitter tract (eg: isolation of the nigrostriatal dopamine 
pathway) or portions of the same neurotransmitter tract (eg: separation of 5-HT terminals in 
the ventral tegmental area from 5-HT cell bodies in the dorsal raphe nucleus).   
 Mouse brain slices are a robust and controlled preparation for the isolation and 
maintenance of brain regions for analytical studies.  The brain can be divided along three 
planes: horizontal, sagittal, and coronal.  Figure 1.3 shows examples of these three sections 
and how they are taken from a human brain.  The nomenclature described in Figure 1.3 is 
identical for sections taken from the mouse brain.  Using a reference atlas such as The 
Mouse Brain in Stereotaxic Coordinates by Keith Franklin and George Paxinos (Paxinos et 
al., 1985), it is possible to pinpoint an anatomical location within a brain slice.  When the 
area of interest is contained within a thin section of live tissue, it can be maintained under 
physiological conditions for study.  The brain slice preparation is particularly useful for  
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Figure 1.2  The action potential propagating down an axon. 1)  Voltage gated channels 
open allowing Na+ to flow in along its concentration gradient.  The membrane potential shifts 
to a more positive potential (blue coloration) called depolarization.  2)  Behind the region of 
more positive membrane potential K + rushes out of voltage gated K + channels.  This leads 
to a hyperpolarized region of membrane (green coloration).  3)  Both the depolarized and 
hyperpolarized regions move along the axon as voltage gated Na + and K + channels open 
and close. Illustration can be found at kvhs.nbed.nb.ca.  
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Figure 1.3  Slicing planes used in the section of the human brain.  Center: The three 
dimensional brain showing the section planes.  Top Left:  An example coronal slice in which 
the brain is sliced from dorsal surface to the ventral surface perpendicular to the horizontal 
plane.  Top Right:  Sagittal slices are still perpendicular to the horizontal plane but are taken 
from the anterior to posterior surfaces.  Bottom Left: A horizontal slice is taken from the 
anterior surface to the posterior surface but is perpendicular to the coronal plane.  Graphic 
modified from http://homepage.smc.edu/russell_richard. 
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isolating and studying midbrain structures which are occluded by the cortex and difficult to 
visualize and access when the brain remains intact (Kandel, 2008).  Slices are prepared 
according to the structures and anatomical orientation deemed most appropriate to answer 
the specific question of interest.  For example, the isolation of the intact nigrostriatal 
dopamine pathway is best achieved using a sagittal or horizontal section while isolation of 
the dopamine terminal region is best done with a coronal section.  A brain slice is shown in 
Figure 1.4 where the nigrostriatal dopamine pathway has been visualized with 
immunoperoxidase staining of the dopamine transporter (DAT) (Salahpour et al., 2008).  
Had this slice been maintained in a viable state rather than fixed, it would have been 
possible to do spatially resolved studies at the cell bodies, terminals, or both. 
Electrochemistry 
 Electrochemistry is a technique through which redox chemistry can be used to study 
electroactive species at the surface of an electrode.  Direct monitoring of neurotransmitter 
concentration changes over time is important to properly understand their actions in the 
brain.  This dissertation focuses on the use of two types of electrochemistry to monitor 
biogenic amines: fast scan cyclic voltammetry (FSCV) and constant potential amperometry 
(referred to hereafter as amperometry).  The analytical sensor used was a carbon fiber 
microelectrode (CFME) (Cahill et al., 1996). 
 FSCV at CFMEs is a useful method to evaluate the concentration of biogenic amines 
and its rapid changes.  In FSCV, a linear voltage ramp is used to oxidize and reduce 
species of interest at an electrode surface.  FSCV at CFMEs has the ability to monitor small 
changes in analyte concentration while in a complex mixture.  Monitoring neurotransmitter 
release in brain tissue is subject to a unique set of analytical problems: closely resolved 
anatomical structures require a small sensor, nanomolar analyte concentrations require a  
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Figure 1.4  A sagittal section of the mouse brain.  This section has been stained with 
immunoperoxidase to visualize the dopamine transporter (DAT).  The DAT is located in high 
density on dopamine terminals and cell bodies making them appear darker than the 
surrounding tissue (Salahpour et al., 2008).   
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sensitive technique, and a host of interfering compounds requires selectivity for the analyte 
of interest.  Also, subsecond time resolution is necessary to effectively monitor real time 
release and uptake events in biological tissue (Venton et al., 2002).  The cylindrical T-650 
CFME used in this work is 6 µm in diameter and cut to a length of 50 µm, providing very 
good spatial resolution (Figure 1.5) (Kawagoe et al., 1993; Cahill et al., 1996).  Carbon 
fibers provide enhanced sensitivity by adsorbing biogenic amines when held at a negative 
potential (Heien et al., 2003).   
The peak faradaic current at a voltammetric electrode can be defined by (Bard and 
Faulkner, 2001): 
݅௣ ൌ ሺ2.69 ൈ 10ହሻ݊ଷ/ଶܣܦை
ଵ/ଶܥைכ ݒଵ/ଶ                                                        ሺ1ሻ      
where n is the number of electrons, A is the electrode area, DO is the diffusion rate of the 
oxidant, Co is the concentration of the oxidant, and v is the scan rate.  This equation predicts 
that the peak faradaic current should increase as the square root of the scan rate, but it only 
applies to a freely diffusing, non-adsorbed oxidant in solution.  When an analyte is adsorbed 
to the electrode surface its peak faradaic current scales proportionally with scan rate, 
enhancing the analytical signal associated with the same concentration of non-adsorbed 
analyte at a given scan rate.  The adsorption of analyte on the sensor surface enhances the 
electrochemical signal by preconcentrating the analyte and changing its electrochemical 
properties.   
 The selectivity and temporal resolution required to monitor neurotransmission is 
provided by performing FSCV at the CFME.  The use of an ultra-microelectrode such as a 
CFME permits the use of faster scan rates by reducing the ohmic drop and RC time 
constant of the electrode (Wightman et al., 1988).  Typical scan rates used in this work 
range from 600 V/s to 1000 V/s applied at 10 Hz or 60 Hz.  Therefore, the ultimate time  
10 
 
 
 
 
Figure 1.5  A cylindrical T-650 carbon fiber microelectrode.  A T-650 carbon fiber has been 
sealed in a glass capillary and cut to a length suitable for experimentation.  The glass seal 
can be seen in the right hand portion of the panel.  The fiber has a diameter of 6 µm and is 
typically cut to a length of 50 µm (Cahill et al., 1996).  Scale Bar: 10 µm. 
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resolution of the CFME using FSCV under these conditions would be 100 ms for 10 Hz and 
16.7 ms for 60 Hz.  Other techniques used to monitor neurotransmission, such as 
microdialysis, normally operate on the minute time scale.  The fastest demonstrated 
microdialysis measurements were made 15 s apart using stepped flow sampling (Wang et 
al., 2008). 
 A second advantage to FSCV is the selectivity achieved using the cyclic 
voltammogram (CV) for identification of an analyte.  Figure 1.6 shows the structures, voltage 
ramps, and CVs for dopamine and 5-HT.  The positive current arises from oxidation of 
dopamine or 5-HT accumulated on the electrode surface in the time between scans (either 
100 ms or 16.7 ms) while the negative current is the reduction of oxidized analyte remaining 
on the electrode surface.  The positive and negative current deflections occur at a 
characteristic potential for each analyte, allowing the identity and presence of the analyte to 
be verified in a complex mixture of proteins, lipids, other neurotransmitters, and dissolved 
gases.  Notice that the ramp used for 5-HT is different than that for dopamine (Figure 1.6).  
The electrochemistry of 5-HT is more complicated than dopamine, requiring a more complex 
waveform to prevent the accumulation of interfering species that form when 5-HT is oxidized 
(Jackson et al., 1995).  Figure 1.6 also shows that although the voltammetric waveforms are 
very different, the oxidation of both analytes occurs at a similar potential.  This similarity 
should prevent positive identification of 5-HT over dopamine if both were present in a 
mixture.  However, the ramp provides enhanced sensitivity for 5-HT over dopamine because 
the electrode rests at a positive potential preventing dopamine adsorption (Jackson et al., 
1995).  This waveform makes the electrode insensitive to physiological dopamine 
concentrations and allows for exclusive monitoring of 5-HT in the presence of dopamine.  
Therefore, the FSCV potential ramp can be used to impart selectivity on the electrode if the 
CVs of two species do not facilitate positive identification. 
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Figure 1.6  Example voltammograms of two biogenic amines.  Left Panels:  Dopamine is 
detected using a linear voltage ramp from -400 mV to 1,000 mV back to -400 mV scanned at 
600 V/s.  The dopamine CV is characterized by an ip,c at 650 mV and an ip,a at -200 mV.  
Right Panels: 5-HT detection requires a more complicated waveform where the voltage rests 
at 200 mV ramps to 1,000 mV and back to -100 mV at 1,000 V/s holding again at 200 mV 
between scans.  This waveform keeps the electrode clear of fouling products.  The 5-HT CV 
is characterized by an ip,c at 600 mV and an ip,a at 0 mV.  
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An unavoidable effect of scanning a voltammetric electrode quickly is the large 
background current associated with charging of the double layer capacitance.  The 
background current swamps out the relatively small faradaic current associated with analyte 
detection.  For example, the background of a typical 50 µm cylinder electrode may be as 
high as 1000 nA while the current due to dopamine oxidation is typically less than 10 nA.  To 
get around this problem, background subtracted FSCV is used (Figure 1.7).  The 
background is stable over the time period of the measurement and can be removed by 
subtraction leaving only the faradaic current associated with analyte detection. 
 Amperometry is used when greater temporal response is necessary.  In FSCV, there 
is a time delay associated with the adsorption and desorption of the analyte from the 
electrode surface (Heien et al., 2003).  These events slow the electrode response to 
changes in analyte concentration (Bath et al., 2000).  In amperometry the electrode is held 
at a constant potential sufficient to oxidize the analyte of interest (700 mV for dopamine).  
When the analyte encounters the electrode surface it is immediately oxidized and a signal 
recorded (Hochstetler et al., 2000).  The lack of any adsorption or desorption means that the 
temporal response is only limited by mass transport and electron transfer kinetics.  The net 
result is a faster response time than FSCV (Mundroff and Wightman, 2002).  Amperometric 
measurements are less sensitive (almost 100 fold for dopamine) than FSCV due to a lack of 
preconcentration; however, similar S/N ratios have been reported for the two techniques 
(Venton et al., 2002).  Unfortunately, the lack of an analyte-specific cyclic voltammogram 
prevents analyte identification.  For this reason amperometry is generally only used once the 
identity of the electrochemical signal has been established. 
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Figure 1.7  The charging current associated with fast scan rates is large compared to the 
Faradaic current associated with dopamine detection.  The background remains relatively 
unchanged over the measurement time and can be subtracted out digitally (midddle panel 
less the top panel) revealing a CV of dopamine alone.  
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Brain Slice Measurements 
 Brain slices are a robust and reliable tissue preparation to be used in 
electroanalytical studies.  In a brain slice experiment, neurotransmitter release is typically 
evoked by a current pulse through a bi-polar stimulating electrode and monitored at the 
working electrode (Figure 1.8).  The data from the working electrode is viewed in two ways: 
the CV (as shown in Figure 1.7), used for substance identification, and the current trace, 
generated by monitoring the oxidation potential for changes over time (Figure 1.8).  The 
current trace is then translated into a concentration trace by calibrating the electrode against 
a known concentration of analyte (see chapter 2).  The concentration trace has two distinct 
phases that occur after electrical stimulation.  There is an instantaneous rise in amine 
concentration after stimulation followed by clearance through presynaptic uptake 
transporters (Figure 1.8).  The environment of the slice can be modified by changing ion 
concentrations, applying drugs, or changing temperature to modify the size and shape of 
this basic curve.   
 Brain slice experiments are particularly informative when monitoring uptake kinetics.  
The uptake of biogenic amines can be effectively modeled using Michaelis-Menten kinetics 
where the transporter is treated as the enzyme and the neurotransmitter as the substrate.  
Based on these approximations, the concentration of amine can be expressed as a function 
of time for a single pulse stimulation:  
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                                                       ሺ2ሻ     
Based on this equation the uptake parameters Km (the binding affinity for dopamine at the 
transporter) and Vmax (the maximal rate of dopamine uptake) can be calculated for different 
locations, animal types, and environmental conditions.  The Michaelis-Menten model is a  
16 
 
 
 
 
Figure 1.8  An example of stimulated dopamine release in a striatal brain slice.  Top Panel:  
A brightfield image of the two-pronged tungsten stimulating electrode placed on the slice 
surface and the CFME placed 100 µm away.  The stimulus is provided through the tungsten 
electrode and dopamine is measured at the working electrode.  Bottom Panel:  The [DA] as 
a function of time in response to the stimulus.  The stim, release portion, and uptake portion 
of the curve are marked.  
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robust and effective way to measure clearance rates (Wightman et al., 1988; Wu et al., 
2001).  A more detailed explanation of how uptake rates can change in the brain will be 
explained in later chapters. 
High Performance Liquid Chromatography 
 High performance liquid chromatography (HPLC) with electrochemical detection is 
an important technique for the support and validation of electrochemical monitoring of 
biogenic amines using CFMEs in brain slices.  HPLC is most often used as the analytical 
sensor associated with microdialysis measurements (Umriukhin et al., 2007; Howard et al., 
2008; Wang et al., 2008).  Chapter 6 focuses on the use of HPLC in support of 
electrochemical data by providing information about the content of amines in a particular 
brain region.  HPLC is run using an amperometric detector incapable of differentiating 
between different biogenic amines electrochemically.  The selectivity of the HPLC 
measurement arises from a polarity based separation mechanism which resolves biogenic 
amines temporally (Figure 1.9).  An additional analytical technique like HPLC is often 
needed because, although powerful, FSCV is unable to determine the total biogenic amine 
profile for a particular brain region.  Total content is also important data to have in cases 
where the amount of dopamine being released has been altered in some way (Senior et al., 
2008).  The combination of electrochemical and chromatographic data provides better 
understanding of the mechanism of the release change by separating changes in dopamine 
available for release and an increased release probability of dopamine.  LC total content 
measurements are also powerful when looking at regions with interfering substances.  The 
total content measurements can verify or refute the presence of a neurotransmitter that 
cannot be distinguished from the analyte of interest using FSCV. 
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Figure 1.9  An isocratic reverse phase separation of several biogenic amines using reverse 
phase HPLC with electrochemical detection.  Analytes are separated temporally based on 
their relative polarity and detected by amperometry.  The x-coordinate is the elution time in 
minutes while the y-coordinate shows the oxidation current of each species.  Peak 
Assignments; 1) Solvent front 2) norephinephrine 3) hydroquinone (quantification standard) 
4) l-dopa 5) epinephrine.  
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Transgenic Mouse Models 
 In 2007, Oliver Smithies shared the Nobel Prize in Medicine with Sir Martin Evans 
and Mario Capecchi for their contributions to the field of transgenic mutagenesis.  In 
particular, their research was central to the development of embryonic stem (ES) cells as 
vehicles for specific gene mutations.  The role of transgenic mice in the development of 
disease state models cannot be downplayed.  Mouse models such as these can be credited 
with the development of new Alzheimer’s treatments, diabetes drugs, and the advancement 
of heart disease research among other things.  A few more examples of the impact made by 
transgenic mice in the medical field can be found in the following references (Adlard et al., 
2008; Bjorkqvist et al., 2008; Choi et al., 2008; Pattison and Robbins, 2008; Seidler et al., 
2008).  The two most common generation techniques are direct transfection or ES cells 
transfection of fertilized embryos. 
 The first technique involves the direct introduction of foreign DNA into a fertilized 
mouse embryo.  The introduction of the foreign DNA can be performed by pronuclear 
injection, retroviral infection, or adenoviral infection.  Pronuclear injection requires the 
introduction of foreign DNA by micropipette directly into the fertilized egg.  Transfected eggs 
are then implanted into a pseudo-pregnant female who gives birth to a founder animal (a 
pup that expresses the transgene).  Once germline transmission of the transgene is 
complete, many generations are mated to create homozygous transgenic animals.  This 
technique is more technically controlled than the viral transfection techniques, but requires a 
longer training period for proficiency and more expensive equipment.  Pronuclear injection 
technique can also yield unreliable transfection results because the number of incorporated 
transgene copies is unknown, and the expression of the transgene can be affected by its 
local chromosomal environment. 
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Viral transfection involves the incubation of a fertilized egg with adeno or 
retroviruses.  These viruses are unable to replicate their own genome because they have 
had selected genetic deletions preventing it.  Even though replication is prevented, the virus 
is still able to interpolate some foreign DNA into the host egg for replication.  Viral 
transfection of fertilized eggs is more cost effective than pronuclear injection, but does have 
limitations.  Only a small amount of exogenous genetic material can be added to the viral 
genome (4-7.5 kb) without making the virus non-functional.  The relatively small amount of 
genetic material that is implantable with this technique makes it impractical for large genetic 
manipulations.  In rare cases, the virus can undergo recombination with the host genome 
activating its replication ability.  The entire viral genome will then propagate through the host 
egg.  The problems with viral transfection are often outweighed by a simpler and cheaper 
technique than would be possible with pronuclear injection. 
 The development of ES cells as transgene hosts has eliminated many of the 
problems associated with previous methodologies.  ES cells are undifferentiated cells 
capable of replicating to form any type of physiological tissue, and therefore are capable of 
carrying a transgenic manipulation to all cell types.  Under proper conditions they can be 
maintained in an undifferentiated state where the addition of exogenous genetic material 
can occur.  ES cells expressing the desired transgene can then be selected for injection into 
the fertilized egg.  The selection of cells is most often done using a selectable marker gene 
in the transgenic cassette.  The integration of the selectable marker gene will convey 
attributes to the transfected cell such as antibiotic resistance that can be used to isolate it 
from non transfected cells.  There are many different types of selectable markers such as 
NEO or β-GEO which impart neomycin resistance or expression of β-galactosidase 
respectively.  Reporter genes can also be added to the cassette so that the degree of gene 
expression can be monitored in the intact animal. 
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Gene targeting relies on the naturally occurring process of homologous 
recombination to impart characteristics on the host animal.  The first evidence of 
homologous recombination was in the early 1980s between two plasmid molecules, and 
was soon followed by targeting of the first endogenous locus in 1985 (Folger et al., 1982; 
Smithies et al., 1985).  Homologous recombination requires the use of known endogenous 
sequence markers for targeted transfer of genetic material in ES cells.  There are two main 
types of gene targeting: replacement and insertion.  These techniques differ mainly in the 
design of the DNA vector (both contain homologous sequences, reporter genes, selectable 
marker genes, and the transgene).  In general, two flanking regions of homology (at least 
500 bp on the short arm) are used because the length of homology increases the targeting 
frequency (typically only 1:1,000,000 treated cells undergo targeted recombination).  
Replacement vectors are structured so that they contain two separate homologous regions 
separated by non-homologous DNA which is then incorporated into the host DNA replacing 
the area between the homologues.  The vector is cut outside of the region of homology 
forcing the DNA polymerase to replace the endogenous locus during recombination.  The 
insertion vector is linearized within the region of homology inducing the DNA polymerase to 
insert the entire cassette between the regions of homology.  Either technique can be used to 
generate gene knockout mice; however, only insertion can be used to generate a gene 
knock-in animal.   
Most targeted transfections require a double selection process during which ES cells 
that express the gene are selected then screened for proper gene targeting.  A common 
double selection method uses HSVTK (contains NEO and TK marker genes in the cassette). 
The NEO gene provides resistance to neomycin like drugs while the TK gene makes the cell 
susceptible to ganciclovir.  The transgene is created such that homologously transfected 
cells are NEO+TK- and ES cells transfected by random insertion are NEO+TK+.  Selection 
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against G418 (a synthetic neomycin derivative) spares all cells expressing the transgene.  A 
second exposure to ganciclovir only spares cells that have undergone homologous 
recombination because a randomly inserted transgene makes the cell sensitive to 
ganciclovir.  The selected cells are then used to generate a mouse line that has the targeted 
transgene expressed in the correct genetic location.   
 The introduction of genetic material by insertion is more complicated than the 
knockout procedure.  The insertion of genetic material is difficult because the reporter gene 
or selectable marker gene could impede on the expression of the transgene once the 
transgenic animal has been generated.  A method developed to deal with this problem 
utilizes the Cre-loxP system to remove the reporter region after selection (Sunaga et al., 
1997).  This system is a robust way to snip out small sections of genetic material by flanking 
that gene(s) with loxP binding sites.  The enzyme cre recombinase binds and removes the 
genetic material between two loxP binding sites.  Cre recombinase exposure can be done 
while the cells are still in vitro or once the animal has been generated.  An example insertion 
paradigm would use a selectable marker that is flanked by loxP binding sites.  After a 
positive selection is done using the marker to select for cells expressing the transgene, cre 
recombinase is used to remove the selectable marker gene preventing interference with the 
transgene.  A similar removal could be done for any reporter genes that are being used to 
measure transgene expression.  This example is by no means the only use of the Cre-loxP 
system.  Binding sites for cre recombinase could also be placed around endogenous genetic 
material.  Endogenous material could then be silenced at particular times to study the effect 
of a particular gene during development or cut out to generate a knockout animal.  
Performing transgenic manipulations in this way is often referred to as conditional 
transfections.  The use of this system is a more elegant way of transfecting but is not always 
necessary.   
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 A large amount of literature is available for the study of mouse transgenic 
techniques.  The topics discussed here are only a sampling and are derived mainly from 
several sources dedicated to the molecular biology of transgenic mouse generation 
(Scarpelli et al., 1992; Tymms and Kola, 2001; Clarke, 2002; Hofker and Deursen, 2003). 
Thesis Overview 
 The following work focuses on the combination of electrochemistry, brain slices, and 
transgenic mouse models for the evaluation of biogenic amine transmission in the brain.  
Five distinct transgenic mouse models have been used to better understand the 
neurotransmission of dopamine and 5-HT.  A particular emphasis has been placed on 
dopaminergic transmission as it applies to movement phenotypes and drugs of addiction (ie. 
cocaine and methamphetamine).  Collaboration with Marc Caron at Duke University has 
facilitated the study of animals over-expressing the dopamine transporter and how it relates 
to amphetamine sensitivity and movement initiation.  A second transgenic mouse model 
from the lab of George Augustine at Duke University has been used to study the genetic 
deletion of the presynaptic protein synapsin and how it relates to the action of cocaine.  Two 
mouse models were used in collaboration with the lab of Brad Lowell at Harvard University.  
These mice were used to evaluate obesity and ATP utilization and how they apply to 
movement phenotypes and dopamine release.  Finally, dopamine dynamics in Fmr1 KO 
mice were studied in collaboration with the University of Illinois at Urbana-Champagne.  This 
dissertation will clearly demonstrate the power of transgenic mouse models for the 
understanding of neurotransmitter dynamics.   
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Chapter 2 
Materials and Methods 
 
Introduction 
 This chapter explains the primary methods used in the generation of transgenic 
mouse models and the analysis of mouse brain slices with electrochemistry.  The methods 
described here should were used in subsequent chapters unless otherwise noted. 
Transgenic Mouse Models 
Mice used in this study were age and sex matched whenever possible and handled 
via procedures approved by the Institutional Animal Care and Use Committees (IACUC) of 
Duke University, Harvard University, the University of Illinois at Urbana Champagne, and the 
University of North Carolina at Chapel Hill. 
 The DAT-Tg mouse models used in this study were created in the lab of Dr. Marc 
Caron at Duke University according to the procedure published in Salahpour et al. (2008).  A 
bacterial vector (BAC) containing the mouse DAT locus was obtained from Genome 
Sciences (Duke University, Durham NC).  The topology of the BAC was verified using PCR 
analysis.  A BAC clone was chosen for pronuclear injection containing the DAT locus (40 
Kb) flanked by 80 Kb of upstream and downstream genomic homology. The BAC DNA was 
isolated using a Clonetech BAC preparation kit and re-suspended at 2 ng/µl in injection 
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buffer (0.03mM Spermine, 0.07mM Spermidine).  Pro-nuclear injections were carried out by 
the Duke Transgenic Mouse Facility using C57BL/6J embryos.  One transgene positive 
founder was identified by PCR based genotyping with oligos recognizing BAC vector 
sequences (Forward: 5’-gcatcagccagcgcagaaatatttcc, Reverse: 5'-
gatacttcgttatcgacaccagctgc-3') and bred for characterization of the transgene. 
 The synapsin triple knockout (TKO) animals were generated at Duke University in 
the lab of Dr. George Augustine.  The following procedure for the generation of synapsin 
TKO mice and corresponding littermate wild type mice was published in Gitler et al. (2004).  
Synapsin TKO mice were generated by serial breeding of synapsin I knockout (KO) mice 
(Chin et al., 1995), synapsin II KO mice (Ferreira et al., 1998), and synapsin III KO mice 
(Feng et al., 2002).  Genotyping of bred animals was done by PCR using sense and 
antisense primers for synapsin I, synapsin I/II, and synapsin III.  Western blots were used to 
confirm the presence or absence of the synapsin proteins.  Synapsin TKO mice are on a 
mixed genetic background. 
 Leptin deficient (ob/ob mice) are available for purchase through Jackson 
Laboratories (Bar Hardbor, ME.).  The ob/ob mice used in these studies were on a C57BL/6 
background and were discovered by chance in a colony at Jackson Laboratories.  Mice 
lacking UCP2 were also generated on a C57 BL/6 background in the lab of Dr. Brad Lowell 
at Harvard University using ES cell transfection techniques as previously described (Zhang 
et al., 2001).  Briefly, a targeted replacement of the Ucp2 gene including a portion of the 
start codon was performed using a replacement cassette.  Properly transfected ES cells 
were injected into mouse blastocysts generating a germline from which WT, heterozygous 
UCP2 KOs, and homozygous UCP2 KOs were bred.  Successful deletion of UCP2 was 
confirmed by Southern blot analysis and multiplex PCR.  
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 Mice lacking the Fragile X protein gene Fmr1 were generated at the University of 
Illinois by William Greenough.  They are commercially available through Jackson 
Laboratories (Bar Harbor, ME.).  A complete discussion of their generation can be found in a 
paper from the Dutch Consortium (1994).  Briefly, a targeted vector was used to disrupt the 
5’ axon of the Fmr1 gene in ES cells.  Properly targeted ES cells were selected and injected 
into blastocysts from C57BL/6 mice. 
Electrochemistry 
Cylindrical carbon-fiber microelectrodes (6 µm diameter, Thornel T-650, Amoco, 
Greenville, SC) were fabricated as previously described (Bath et al., 2000).  Carbon fibers 
were aspirated into glass capillary (1.2 mm X 0.68 mm, 4”, AM Systems, Carlsborg, WA.).  
The electrodes were pulled on a vertical capillary puller (Narishige) and the excess carbon 
fiber was trimmed to 50 µm.  Waveform application, current monitoring, and stimulus 
application were all controlled by locally written software (Tarheel CV, Labview) through a 
home built potentiostat (UEI, UNC electronics shop).   
For dopamine and NE detection, the carbon-fiber electrode was held at -400 mV vs. 
a Ag/AgCl reference electrode between voltage scans.  Detection in brain slices was 
achieved by application of a triangular waveform: -400 mV to 1,000 mV to -400 mV at a 
scan rate of 600 V/s repeated every 16.7 or 100 ms.  This waveform provides high temporal 
resolution while maintaining good sensitivity (Bath et al., 2000).  The waveform for in vivo 
use employed the same voltages, but at 300 V/s and repeated every 100 ms; this method 
provides improved sensitivity but decreased time resolution (Baur et al., 1988).  The current 
at the peak oxidation potential for dopamine (500-700 mV vs. Ag/AgCl) was used to 
evaluate dopamine concentration changes. 
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For 5-HT detection the electrode potential between scans was 200 mV vs Ag/AgCl.  
The cyclic voltammogram was obtained with an initial scan to 1,000 mV, back to -100 mV, 
and then scanned to 200 mV at 1000 V/s applied every 100 ms.  The positive rest potential 
minimizes electrode fouling from 5-HT reduction products (Jackson et al., 1995).  In addition, 
the rapid scan rate prevents side reactions characteristic of the electrochemical detection of 
5-HT from contributing to the current signal (Jackson et al., 1995).  The positive potential 
also decreases the electrode’s sensitivity to dopamine by at least 100 fold.  For dopamine, 
NE, and 5-HT, the electrodes were calibrated in a flow injection system with a 1 µM bolus of 
analyte. 
Amperometry experiments were performed using the same equipment as the FSCV 
measurements or an Axopatch 200B (Axon Instruments).  For biogenic amine 
measurements by amperometry, the electrode was held at a potential sufficient for oxidation 
(700 mV vs. Ag/AgCl).  Ascorbic acid (500 µM) was added to the slice and calibration 
buffers to enhance the amperometric signal and allow for calibration of the electrode 
(Venton et al., 2002).  Amperometric electrodes were calibrated in a flow injection system 
against 1 µM dopamine in buffer containing 500 µM ascorbate.   
Slice Experiments 
Mice were anesthetized with ether and decapitated.  The brain was rapidly removed 
and placed on ice.  Coronal brain slices (300 µm thick) containing the caudate putamen, 
substantia nigra pars reticulata (SNr), or the ventral bed nucleus of the stria terminalis 
(vBNST), were prepared in ice cold artificial cerebral spinal fluid (aCSF) using a Lancer 
Vibratome (World Precision Instruments, Sarasota, Fl.).  The aCSF contained (in mM): 20 
HEPES, 2.4 CaCl2, 1.2 MgCl2, 1.2 NaH2PO4, 2.45 KCl, 126 NaCl, 11 glucose, and 25 
NaHCO3.  The pH was adjusted to pH 7.4 and the aCSF was saturated with 95% O2 / 5% 
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CO2.  Slices were superfused in aCSF at 37 oC for 35-40 minutes prior to recording.  
Recordings were performed on a microscope (Nikon FN1, Gibraltar Stage) fitted with a slice 
perfusion chamber (Warner Instruments, Hamden CT). 
 Neurotransmitter release was evoked by local electrical stimulation delivered through 
a tungsten bipolar stimulating electrode placed on the surface of the slice (Frederick Haer 
Co., Bowdoinham, ME).  The stimulation consisted of a computer generated, biphasic (2 ms 
per phase), constant-current (350 µA) pulse.  A single stimulation pulse was used to evoke 
striatal dopamine release in the caudate putamen (Jones et al., 1995), a 20 pulse 100 Hz 
stimulation train was used to evoke 5-HT release in the SNr (Bunin et al., 1998), and a 60 
pulse 60 Hz stimulation was used to evoke NE release in the vBNST (Miles et al., 2002).  
The current pulse was optically isolated from the preparation (NL 800, Neurolog, Medical 
Systems, Great Neck, NY).  Stimulations were performed at regular 3-5 intervals to maintain 
consistent release.  Neurotransmitter release was detected at a carbon-fiber microelectrode 
placed 75-100 µm into the slice at a distance of 100-200 µm from the stimulating electrode.  
Electrode placements were made with the aid of the microscope.   
To determine the amount of dopamine release in transgenic animals, the maximal 
release at 4 locations in a single slice was recorded over a 20 minute period, and the values 
were averaged together.  The responses from animals of each genotype were pooled.  The 
amount of 5-HT released was determined in a similar fashion to dopamine with the 
exception that three locations were used.  A single release site was used for NE 
measurements in the vBNST.  The number of sites used for each neurotransmitter was 
determined based on brain region size and release heterogeneity within that brain region.  
Single site recordings were used anytime an experiment required the manipulation of the 
slice environment to minimize the contribution of spatial heterogeneity to the measured 
signal.  Slices were given a 35 minute recovery period every time the environment was 
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changed by manipulation of external ion concentrations or by the application of a drug.  An 
additional 35 minutes was given if the concentration of external ion or drug was changed.  
Some drugs (l-dopa and tetrabenazine) required an incubation time of 1 hour prior to 
recording.  With the exception of l-dopa (1 hour incubation followed by a 35 minute rinse 
with aCSF), all drugs remained in the perfusion buffer for the entirety of the measurement.   
Slice experiments utilized two types of background subtraction to remove the large 
currents associated with double layer charging that occurs when scanning voltages quickly.  
Stimulated dopamine release experiments used traditional digital background subtraction 
techniques (Michael et al., 1999).  In cases where basal dopamine concentrations were 
calculated using principal component regression (reverse transport in Chapter 7), analog 
background subtraction was used.  Analog background subtraction was performed as 
previously described (Hermans et al., 2008).  Unless specified, all data was collected using 
the traditional digital background subtraction methodology. 
Electrochemical Data Analysis 
Dopamine release profiles from striatal brain slices were used to quantify the 
maximal dopamine release for different animal genotypes.  The maximal dopamine released 
([DA]max) was determined using an electrode calibration factor and the current recorded at 
the oxidation potential of dopamine (650 mV vs. Ag/AgCl).  These [DA]max values are 
reported as being the value of dopamine release for a particular area or type of animal.  The 
same technique was used for the neurotransmitters 5-HT and NE whose maximum attained 
concentrations were determined from calibrated current traces.  Changes in basal dopamine 
levels were determined differently than stimulated release by using principal component 
regression as described previously (Heien et al., 2004).  Briefly, mathematic algorithms were 
used to divide the current signal into contributing components.  In brain slices, these 
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components were generally limited to dopamine concentration changes, background drift, 
and electrode capacitance changes.  Removal of components that are not dopamine related 
facilitates a more accurate description of dopamine dynamics over long times.  This 
technique was not used for stimulated release experiments because the time course of 
dopamine concentration changes (< 1 sec) was too short for appreciable signal contributions 
from factors other than dopamine. 
Current responses for a particular animal genotype or brain location were pooled 
prior to further data analysis.  All data shown are written as mean ± standard error in the 
mean (SEM).  The n values are the number of animals used for a specific experiment.  In 
addition to this replicate number, multiple locations and stimulations were used to reduce 
random error in the electrochemical measurements. Tests of significance included Student’s 
t-test and one way ANOVA where applicable.   
Simplex Modeling 
 Simplex modeling was used to extract kinetic constants associated with the uptake of 
dopamine and 5-HT from the extracellular space.  Concentration traces were modeled using 
a Michaelis-Menten based non-linear regression model (Wightman et al., 1988).  For a 
dopamine trace, modeling extracts dopamine per pulse (DAp), maximal uptake rate (Vmax), 
and transporter affinity for dopamine or 5-HT (Km) values from the trace.  Simplex modeling 
requires deconvolution of the FSCV signal from the adsorption/desorption time delay by 
using an electrode time constant (15-50 ms for a 60 Hz sampling rate).  Deconvolution of 
the signal for the adsorptive time delay facilitated more accurate modeling of the uptake 
kinetics (Venton et al., 2002).  When determining Vmax values, the Km value was fixed at 200 
nM (Near et al., 1988) for dopamine and 170 nM for 5-HT (John et al., 2006).  When 
competitive uptake inhibitors were used such as cocaine, a Vmax value is determined from 
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simplex using predrug files for the measurement site.  Once Vmax for a particular location 
was determined, it was fixed and changes in Km (Km(app)) were accurately measured.  
Simplex modeling facilitated the robust and accurate determintation of Michaelis-Menten 
uptake kinetics from FSCV measurements (Wu et al., 2001). 
Km Determination 
 The binding affinity of dopamine for the DAT was determined using two methods: 
cocaine inhibition and amperometric modeling.  Single site measurements were performed 
using a 60 Hz collection frequency and a single pulse stimulation in coronal brain slices of 
the mouse caudate putamen.  A stable baseline of 50 minutes was prerequisite to any drug 
application and used to determine an initial Vmax value for the study location.  Cocaine was 
applied through the superfusion buffer for 35 minutes prior to drug files being recorded.  A 
linearized curve was generated using ascending concentrations of cocaine (1, 2, 5, 10, 20, 
and 30 µM).  The curve represented the Km(app) as a function of cocaine concentration.  The 
y-intercept of the line is the Km(app) without any inhibitor on board which is equivalent to the 
original Km.  These Km values could be compared for the genotypes in question. 
Amperometry was used to directly evaluate the kinetics of dopamine uptake.  In this 
experiment, Vmax and Km were measured at three locations in the caudate.  An initial large 
stimulation was used to evoke 2 µM dopamine; the slope of line taken between [DA]max and 
½ [DA]max was estimated to be the Vmax value for that location.  Once Vmax had been 
determined, a smaller stimulation current was used to evoke dopamine release at a 
concentration of 400 nM.  The resultant curve was modeled with an exponential decay 
function which effectively mimics dopamine uptake at low concentrations of dopamine.  
Using this function, and the Vmax value obtained for the recording site, a Km value was 
calculated. 
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High Performance Liquid Chromatography 
Tissue samples were dissected from a slice (300-500 µm in thickness) containing the 
region of interest.  The tissue was weighed and homogenized with a wand sonicator (Fisher 
Scientific) in 200-500 µL 0.1 N perchloric acid spiked with 1 µM hydroquinone (HQ) or 1 µM 
acetamidophenol (AP).  Following centrifugation at 6,000 rpm for 10 min, the supernatant 
was removed and filtered with a 0.2 µm syringe filter unit (Millex-LG).  Iontophoretic studies 
were done by ejecting analytes into a known volume of 0.1 N perchloric acid (Herr et al., 
2008).  Injections (10 or 50 µL) were made onto a reverse phase column (C-18, 5 µm, 4.6 x 
250 mm, Waters symmetry 300 or Waters Atlantis T3).  The mobile phase (prepared in 
HPLC grade water) contained 0.1 M citric acid, 0.1 mM EDTA, and 1 mM hexyl sodium 
sulfate, pH 3.5.  Methanol was added as the organic modifier at a concentration of 5-10 % to 
shorten analyte elution times.  Catecholamines were detected with a thin-layer radial 
electrochemical flowcell (BASi, West Lafayette, IN, USA), with the working electrode at 700 
mV vs. a Ag/AgCl reference electrode (BASi, West Lafayette, IN, USA).  Catecholamine 
standards were prepared from 10 mM stock solutions in 0.1 N perchloric acid.  The HQ or 
AP (1 µM) was used as an internal standard for analyte quantification and recovery.  All 
analyte response ratios were taken with respect to the internal standard to account for 
differential electrode responses. 
Chromatographic Data Analysis 
The determination of peak areas for HPLC total content measurements was 
performed using custom written Igor programs.  These programs were designed in the 
Jorgenson lab at UNC-CH.  Peak area determination was performed using statistical 
moments regression theory (Hsieh and Jorgenson, 1996).  The peak area of the analyte 
was taken as a ratio to that of an internal standard at a known concentration, adjusted for 
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differential detector response.  The ratio was then used to calculate a mass of analyte in the 
extraction solution which was normalized by the mass of tissue taken.  Again, n dictates the 
number of animals used; however, replicate extractions and injections were performed to 
reduce random error in the chromatographic measurements.   
Drugs and Reagents 
 All drugs were used as received and dissolved in either doubly deionized water or a 
mixture of doubly deionized water and ethanol.  Cocaine, amphetamine, methamphetamine, 
CNQX, picrotoxin, and buproprion were purchased from Sigma Aldrich.  The dopamine 
uptake blocker PTT was a gift from Dr. F. Ivy Carroll through Dr. Marc Caron.  Reagents for 
buffers and mobile phases were also purchased from Sigma Aldrich and prepared in doubly 
deionized water or HPLC grade water respectively. 
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Chapter 3 
Synapsins and Dopamine Release 
 
Introduction 
Synapsins are phosphoproteins that bind to the cytosolic surface of synaptic vesicles 
and represent almost 10% of the total protein content of synaptic vesicles.  There are three 
synapsins genes (synapsin I, II, and III), with alternative splicing creating 10 known synapsin 
isoforms.  They are differentially expressed in nerve terminals, with synapsins I and II 
predominant in most areas of the adult brain, although synapsin III is present in some 
regions including the dorsolateral striatum (Pieribone et al., 2002).  Synapsins are thought to 
play a role in segregating vesicles into a reserve pool that is located away from the active 
zone, where exocytosis occurs (Greengard et al., 1993).  Early evidence supporting this 
proposal include observations that perturbing synapsins by microinjection disrupts a distal, 
reserve pool of vesicles, while sparing vesicles in the active zone (Pieribone et al., 1995).  It 
is thought that mobilization of vesicles from the reserve pool is triggered by the elevation of 
presynaptic calcium resulting in phosphorylation of synapsins (Llinas et al., 1991; Greengard 
et al., 1993; Chi et al., 2003).  More recent evidence has shown that synapsins are also 
important regulators of exocytosis, vesicle recycling, and vesicle integrity at the active zone; 
furthermore, these actions differ depending on the type of neurotransmitter terminal (Fdez 
and Hilfiker, 2006; Evergren et al., 2007). 
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Synapsin knockout mice have provided insight into the role of synapsins in regulating 
neurotransmitter release.  While deletion of individual synapsin genes (Ferreira et al., 2000; 
Feng et al., 2002) or genes for both synapsins I and II (Rosahl et al., 1995; Lonart and 
Simsek-Duran, 2006), affect the reserve pool of synaptic vesicles, interpretation of results 
from such genotypes are hindered by possible compensation caused by remaining synapsin 
forms and differential expression of synapsins in different brain regions.  These problems 
are solved in triple knockout mice (TKO) which lack all three known synapsin genes.  TKO 
mice exhibit reduced reserve pools in both glutamatergic and GABAergic nerve terminals, 
evident both as changes in vesicle distribution, changes in neurotransmitter release during 
trains of action potentials, and defective release of GABA in response to single action 
potentials (Gitler et al., 2004).  
This chapter extends the discussion of synapsin by examining the release of two 
other neurotransmitters, dopamine and serotonin (5-HT) in synapsin TKO mice. Prior work 
showed that the vesicular transporter for both dopamine and 5-HT, VMAT2 (Erickson et al., 
1996), is found in terminals devoid of synapsin I and II (Bogen et al., 2006).  In contrast, 
synapsin III expression in the adult brain has been confirmed in the striatum (Pieribone et 
al., 2002) but not the SNr.  To determine whether dopamine release is altered in mice 
lacking all synapsins we compared striatal dopamine release from synapsin TKO mice and 
wild-type (WT) mice both in brain slices and in vivo.  Surprisingly, in both cases, dopamine 
release was enhanced in the absence of synapsins.  In contrast, 5-HT release was identical 
in the two types of mice.  The dependence of dopamine release on extracellular calcium 
was found to differ in TKO and WT mice, with TKO mice being more sensitive.  The ability of 
cocaine to increase release of dopamine was reduced in synapsin TKO mice, supporting the 
assertion that synapsins, specifically synapsin III, contribute to the presynaptic actions of 
cocaine (Venton et al., 2006).  In contrast, while cocaine inhibited 5-HT uptake, it did not 
42 
 
affect release of 5-HT in either genotype.  These findings demonstrate that neurotransmitter 
release from terminals differs as a function of the specific regulatory role played by the 
synapsins they contain.   
Materials and Methods 
The experimental procedures used in this chapter have been explained in detail in 
Chapter 2.  The in vivo recordings show in Figure 3.3 were performed by Jill Venton while 
she was a graduate student in our lab and have been included here to improve clarity and 
completeness. 
Results 
Serotonin Release in Substantia Nigra Brain Slices 
 The influence of synapsins on electrically evoked release of 5-HT (Bunin et al., 1998) 
was evaluated by comparing 5-HT release in TKO and WT mice.  Local electrical 
stimulations were used to evoke 5-HT release in slices containing the SNr.  A stimulus train 
consisting of 20 pulses at 100 Hz was used to evoke 5-HT release and cyclic voltammetry 
(Figure 3.1A inset) was used to positively identify the released substance as 5-HT (Bunin et 
al., 1998).  5-HT release evoked under such conditions was stable over several hours if the 
stimulus trains were separated by intervals of 5 min or longer (Bunin et al., 1998).  To 
minimize the contribution of spatial heterogeneity of 5-HT release sites, measurements were 
made at 3 different positions of the carbon-fiber electrode within each SNr slice and then 
averaged together. 
In slices from both genotypes, 5-HT release began promptly at the onset of the 
stimulus and ended as soon as the stimulus stopped, with the concentration of 5-HT 
returning to prestimulus values over the next 1-2 seconds (Figure 3.1A). 
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Figure 3.1  5-HT release in coronal brain slices containing the SNr of WT and TKO mice 
evoked by a 20 pulse 100 Hz train (black line).  A)  Example responses of stimulated 5-HT 
release; the stimulation was delivered at the time indicated by the horizontal bar.  Inset:  the 
cyclic voltammogram used for identification of 5-HT.  B)  The average release from each 
genotype (n = 11 animals for each genotype) is not significantly different (p > 0.05). 
  
44 
 
Pooled measurements of the peak concentration of released 5-HT ([5-HT]max) from 10 
animals of each genotype showed that mean [5-HT]max was 130 ± 8 nM in wild-type mice 
and 140 ± 7 nM in TKO mice (Figure 3.1B).  These two values are not significantly different 
from each other (p > 0.05).  The maximal rate of 5-HT uptake (Vmax) was compared for WT 
and TKO animals using nonlinear regression to model the decay component of the traces 
(Chapter 2).  The Vmax of 5-HT uptake for WT and TKO animals was 450 ± 70 nM/s and 370 
± 80 nM/s respectively; these values were not significantly different from each other (p > 
0.05).  These Vmax values are similar to those reported previously for measurements made in 
the SNr (John et al., 2006).   
Total 5-HT content in the SNr was also measured by high performance liquid 
chromatography (HPLC).  Tissue punches taken from TKO mice and WT mice (4 animals of 
each genotype) indicated that the tissue levels of 5-HT were not different between the two 
genotypes (Chapter 6, Table 6.1).  Cortical tissue samples were used as negative controls 
and 5-HT was undetectable in tissue from either genotype (data not shown). 
Synapsins Affect Dopamine Release in Striatal Brain Slices 
Local electrical stimulation of coronal brain slices was used to evoke dopamine 
release from terminals in the caudate putamen of synapsin TKO and WT animals.  Again, 
cyclic voltammetry was used to positively identify the signal as dopamine (Figure 3.2A 
inset).  The peak at 600 mV vs Ag/AgCl for the oxidation of dopamine had a potential similar 
to that of 5-HT.  However, the cyclic voltammograms for the two substances differ on the 
reverse scan, with the peak for reduction of the dopamine-o-quinone occurring at ~ -300 mV 
with the waveform employed whereas the reduction peak following 5-HT oxidation occurs at 
a more positive potential (Jackson et al., 1995).   
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Figure 3.2  Dopamine release evoked by a single stimulation pulse (vertical black line) in a 
striatal brain slice from WT or synapsin TKO animals.  A)  Example responses of stimulated 
dopamine release.  Inset:  the cyclic voltammogram used for identification of the 
neurotransmitter as dopamine.  B)  Mean [DA]max from multiple locations of each genotype 
show approximately a two-fold difference in striatal dopamine release (p < 0.001, n = 8 TKO, 
n = 6 WT).  C)  The rate of releasable vesicle recovery measured in both genotypes at pulse 
separations of 5 min., 3 min., and 0.3 sec as a ratio of the first stimulation.  A 5 minute 
stimulus separation is sufficient for release recovery in WT animals (n = 5) while a significant 
reduction ( p < 0.05, n = 5) in neurotransmitter release is seen in TKO animals at stimulus 
numbers six and eight.   
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Evoked dopamine release was evaluated every 5 min at four different sites per 
animal, and the values of maximal dopamine release ([DA]max) determined at each site were 
pooled for each genotype.  In slices from both genotypes, dopamine release was observed 
at the onset of stimulation and then declined back to prestimulus values within 1 s after 
stimulation ceased (Figure 3.2A).  [DA]max was significantly greater (p < 0.01) in brain slices 
from TKO mice than in slices prepared from WT mice, being 1.31 ± 0.09 µM (n = 6) for WT 
and 3.31 ± 0.40 µM (n = 8) for TKO (Figure 3.2B).  Dopamine uptake was evaluated with the 
same procedure described above for 5-HT uptake.  The analysis revealed that the Vmax 
values for dopamine uptake were not significantly different (p > 0.05) between the two 
genotypes, being 6.00 ± 0.40 µM/s for WT and 6.20 ± 0.50 µM/s for TKO.  These values are 
slightly higher than those reported previously in WT mice (Johnson et al., 2006).  To 
determine how AMPA and GABAA receptors affect dopamine release, we repeated these 
measurements in the presence of CNQX, to block AMPA receptors, and picrotoxin, to block 
GABAA receptors.  CNQX increased dopamine release while picrotoxin depressed it; 
however, the difference in [DA]max between genotypes remained unchanged (data not 
shown).  Thus, the difference between TKO and WT mice does not arise from differential 
regulation of dopamine release by AMPA or GABAA receptors.  
The ability of presynaptic terminals to replenish their releasable stores of dopamine 
after stimulation in WT and TKO animals was evaluated by varying the time interval between 
stimuli.  When single pulse stimulations were repeated at 3 Hz (0.33 s between pulses), the 
second pulse in the train was 25 % of the first, and release never recovered in subsequent 
stimulations (Figure 3.2C).  When single pulse stimulations were repeated at 3 minute 
intervals (Figure 3.2C), the response to the second stimulus was only ~70% of that on the 
first stimulus and dopamine release remained at this reduced level with subsequent stimuli.  
Responses in the caudate-putamen from TKO and WT mice were indistinguishable with 
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0.33 s or 3 min between stimulation pulses.  In contrast, release in WT animals was 
statistically identical with each stimulus pulse when they were 5 minutes apart.  Release in 
TKO mice was significantly (p < 0.05, n = 5) reduced in stimulations with pulses 5 min apart.  
These experiments reveal that the single pulse stimulations used in this work in slices from 
both WT and TKO animals require at least 5 minutes before similar release can be evoked.  
This is consistent with the half life (2.4 min) for the conversion of nonreleasable dopamine, 
the location of the majority of dopamine stores, to releasable dopamine observed in the 
striatum of rats (Justice et al., 1988).  The other mechanism for refilling of the releasable 
pool, repackaging of newly synthesized dopamine, has a slightly shorter half life (0.7 
minutes) and is presumed to be the same for both genotypes.   
To determine whether the increased release of dopamine observed in TKO mice was 
due to the striatum containing greater amounts of dopamine, HPLC was used to analyze the 
dopamine content of striatal tissue.  No significant difference in the amount of total striatal 
dopamine was found between the two genotypes (Chapter 6, Table 6.1), indicating that the 
increased amount of dopamine release found in TKO mice is not due to higher brain 
dopamine stores.  However, knowledge of the tissue content allows estimation of the 
maximal extracellular concentration that could be achieved if all available dopamine was 
released by a single pulse stimulation.  The molecular weight of dopamine is 153 g/mole 
and the extracellular volume of the tissue is 20 % (Nicholson and Rice, 1990).  Then, the 
molarity of maximal dopamine release is: 
            (4.97 µg/g tissue) x (1/153 g/mole) x (1 g tissue/0.2 mL) = 162 µM 
This calculated value is almost two orders of magnitude greater than found experimentally 
with single pulse stimulations that cause clear depletion of the releasable store.  Thus, 
consistent with prior studies of release, release in the slice preparation comes from only a 
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fractional amount of the total store (Dobrunz and Stevens, 1997).  Furthermore, this store is 
slowly refilled in tissue from both types of animals.  For this reason, vesicles released are 
termed as part of the readily releasable pool and the remainder the reserve pool from which 
vesicle replenishment occurs in both animals.   
Synapsins Also Affect Striatal Dopamine Release in vivo 
Synapsins influence the amount of dopamine released in vivo as measured in the 
brains of anesthetized TKO and WT mice.  In these experiments, electrical stimulation of the 
medial forebrain bundle (MFB), rather than local electrical stimulation, was used to evoke 
dopamine release in the caudate putamen.  Again, 5 minute intervals between stimuli were 
required to observe consistent dopamine release in response to each stimulus.  Figure 3.3A 
shows averaged measurements of dopamine release measured in TKO and WT mice in 
response to 20 Hz stimuli (0.5 s duration; n = 8 for each genotype).  Note that with MFB 
stimulations, continuous trains release approximately constant amounts of dopamine as is 
found in vivo in rats (Wightman et al., 1988).  The amount of dopamine released per 
stimulus pulse ([DA]p) during these trains was found to be significantly different (p < 0.05) in 
the two genotypes, being 90 ± 14 nM for WT and 150 ± 18 nM for TKO mice. 
The loss of synapsins does not affect the frequency dependence of dopamine 
release.  Transmission at dopaminergic synapses is a balance between release and uptake.  
At low stimulus frequencies, the concentration of dopamine reaches a steady plateau 
because uptake and release are balanced, while during high-frequency stimulations the 
dopamine concentration continually increases because the DAT becomes saturated 
(Wightman et al., 1988).  This leads to the different shapes of the release profiles seen in 
Figure 3.3A where release in WT animals approaches steady state to a greater degree than 
release in TKO animals.   
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Figure 3.3  Electrically stimulated dopamine release in the striatum measured in vivo.  A) 
Average release profiles measured in WT and TKO mice (n = 8 for each panel) in response 
to 0.5 s stimulation train at 20 Hz.  B) [DA]max values exhibit similar frequency dependencies 
but release is uniformly greater in TKO animals.  C) A similar dependence on stimulus 
intensity is found in both genotypes although dopamine release is greater in TKO animals. 
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At higher frequencies, greater release was still observed in TKO animals (Figure 3.3B), but 
the differences in shape were much less (data not shown).  We also examined the 
relationship between dopamine concentration and stimulus intensity; in rats, this relationship 
saturates as the stimulation intensity is increased (Wiedemann et al., 1990), due to a 
restricted amount of dopamine available for immediate release.  Although dopamine release 
from TKO animals reached a plateau at the same stimulus intensity (350 µA) as in WT 
animals, the amount of dopamine released was higher at all stimulus intensities (Figure 
3.3C).  This result indicates that TKO mice have a larger immediately releasable pool of 
dopamine.  
Calcium Dependence of Dopamine Release 
 Given the essential role of calcium ions (Ca2+) in triggering neurotransmitter release 
(Augustine and Charlton, 1986; Augustine et al., 1987; Neher, 1998), the effect of synapsin 
loss on the calcium dependence of dopamine release was evaluated.  For this purpose, 
caudate-putamen slices were equilibrated in conventional aCSF containing 2.4 mM Ca2+ 
and dopamine release produced by electrical stimulation was measured at a single location 
that was maintained throughout the experiment while the Ca2+ concentration was varied.  
Treatment with aCSF lacking Ca2+ was then used to remove Ca2+ from the slice and 
extracellular Ca2+ concentration was subsequently increased incrementally from 0.5 mM to 5 
mM.  At each Ca2+ concentration, slices were allowed to equilibrate for 35 min. and then 
stimulated to evoke dopamine release.  To compare the absolute amount of dopamine 
released between genotypes, the release determined at each Ca2+ concentration was 
scaled by the dopamine release at 2.4 mM Ca2+ in WT animals and termed ‘relative 
dopamine release’.  
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Figure 3.4  Calcium dependence of dopamine release in striatal slices.  A)  Relative [DA]max 
for TKO and WT animals at 0-5 mM extracellular Ca2+.  TKO animals release more 
dopamine at all [Ca2+] but experience decreased release at high calcium while WT animals 
are able to maintain maximal release.  B)  Log plot used to determine stoichiometric 
relationship between dopamine release and Ca2+ using a fit to the Hill equation. 
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The Ca2+ dependence of dopamine release differed between TKO and WT animals.  
At all Ca2+ concentrations examined, dopamine release was larger in slices from TKO mice 
than in slices from WT mice.  Furthermore, dopamine release in TKO slices saturated at a 
lower Ca2+ concentration than in WT slices, with saturation occurring at approximately 2 mM 
Ca2+ in TKO slices and 4 mM Ca2+ in WT slices (Figure 3.4A).  The lower saturation level for 
TKO animals indicates a higher affinity for Ca2+ than in WT animals.  At the highest Ca2+ 
levels examined, dopamine release in TKO slices decreased somewhat (Figure 3.4A) but 
such behavior was not observed in slices from WT mice.  This may arise from the slow rate 
of refilling seen for the dopamine readily releasable pool in TKO mice (Figure 3.2C). 
To quantify the relationship between the external Ca2+ concentration and dopamine 
release, the data shown in Figure 3.4A were re-plotted on logarithmic coordinates (Dodge 
and Rahamimoff, 1967; Augustine and Charlton, 1986).  In this case, the sigmoidal 
relationship between Ca2+ concentration and dopamine release is linearized, with the slope 
of the line representing the amount of “cooperativity” in Ca2+ triggering of dopamine release 
and the Ca2+ concentration required for half-maximal dopamine release reflecting the 
apparent Ca2+ affinity, Kca2+ (Dodge and Rahamimoff, 1967).  To determine these two 
parameters, the data was fit using the Hill equation.  Although the shape of the logarithmic 
plots is very similar for dopamine release from both genotypes, we found that the TKO data 
were shifted toward lower Ca2+ concentrations (Figure 3.4B).  This leftward shift was due to 
a difference in the apparent Ca2+ affinity, Kca2+, between the two genotypes, being 1.71 ± 
0.01 mM for WT and 1.13 ± 0.11 mM for TKO animals.  The Hill coefficient was similar for 
both genotypes, being 2.80 ± 0.01 for WT animals and 3.22 ± 0.81 for TKO animals.  These 
values of Hill coefficient are similar to that previously reported for depolarization-evoked 
dopamine release from synaptosomes (Nachshen and Sanchez-Armass, 1987).  Thus, the 
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absence of synapsins raises the apparent Ca2+ affinity of the dopamine release process 
without changing the degree of cooperativity. 
Effects of Cocaine on Dopamine and Serotonin Release 
Synapsins are thought to control a reserve pool of dopaminergic synaptic vesicles 
that is sensitive to cocaine: the ability of cocaine to enhance dopamine release in vivo is 
reduced in synapsin TKO mice (Venton et al., 2006).  The effect of cocaine on 5-HT release 
in SNr brain slices was evaluated by a 35 min application of cocaine (10 µM), a 
concentration that causes competitive uptake of 5-HT transport (John and Jones, 2007) and 
thereby increases the apparent value of Km.  Cocaine treatment caused dramatic changes in 
the shape of the 5-HT concentration profile produced by electrical stimulation, mainly 
prolonging the time course of these signals in slices from both WT and TKO mice (Figure 
3.5, left panels).  To estimate the apparent Km for 5-HT uptake (Jones et al., 1995), we used 
nonlinear regression to evaluate the decaying phase of the 5-HT signal.  The apparent Km 
values in the presence of cocaine were 0.75 ± 0.06 µM for WT and 0.83 ± 0.09 µM for TKO 
animals (n = 7 for WT, n = 6 for TKO), values that are significantly larger than the predrug 
value of 0.17 µM (John et al., 2006).  However, the Km values measured in the presence of 
cocaine are not significantly different from each other (p > 0.05) and are similar to previous 
measurements made for 5-HT uptake in the presence of 10 µM cocaine (John and Jones, 
2007).  In addition, cocaine treatment did not significantly alter the amount of 5-HT released 
by electrical stimulation in slices from either genotype (Figure 3.6).   
 The influence of synapsins on the ability of cocaine to increase dopamine release 
was evaluated.  The effect of cocaine on dopamine release evoked by electrical stimulation 
was compared in caudate-putamen slices prepared from the two mouse genotypes.  These 
slices were treated for 35 minutes with 2 µM cocaine, a dose known to inhibit dopamine 
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uptake in mouse brain slices (Jones et al., 1995).  Although dopamine uptake is much faster 
than that of 5-HT (compare traces in left and right columns of Figure 3.5), the presence of 
cocaine also caused a significant slowing in the time course of the dopamine signal 
produced by electrical stimulation (Figure 3.5, right panels).  This slowing indicates an 
inhibition of dopamine uptake. The apparent Km values for dopamine uptake after application 
of cocaine were 2.60 ± 0.09 µM for WT and 2.60 ± 0.15 TKO µM mice (n = 7 for each 
genotype).  While these values are not significantly different from each other (p > 0.5), they 
are substantially larger than the value of 0.2 µM measured in control conditions.  Cocaine 
treatment also caused an increase in the amount of dopamine released by electrical 
stimulation, evident as an increase in the peak amplitude of the dopamine signals.  This is 
similar to what is observed in rat brain tissue (Jones et al., 1995).  The stimulatory effect of 
cocaine was much greater in slices from WT mice than in slices from TKO mice (Figure 3.5).  
On average, cocaine increased electrically evoked dopamine release by 89 ± 4% in slices 
from WT mice, but only 49 ± 3% in TKO slices (Figure 3.6).  This difference between the 
cocaine responses of the two genotypes is significant (p < 0.001; n = 4 for each genotype).  
We also examined the influence of external Ca2+ on the ability of cocaine to enhance 
dopamine release.  Over the entire range of Ca2+ concentrations considered, cocaine 
caused a greater enhancement of dopamine release from WT slices than from TKO slices.  
To quantify the effects of cocaine on the Ca2+ dependence of dopamine release, the ratio of 
dopamine release measured in the presence and absence of cocaine was calculated 
(Figure 3.7A).  This ratio was significantly greater than 1 at Ca2+ concentrations below 2.4 
mM for WT slices (p < 0.001, n = 6), while TKO slices only showed significant effects of 
cocaine at 1 mM or less Ca2+ (p < 0.01, n = 6).  Figure 3.7B shows the relative dopamine 
release of both gentoypes as a function of the external [Ca2+]. 
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Figure 3.5  Effects of cocaine on stimulated 5-HT and dopamine release and uptake in brain 
slices.  Left Column:  Example responses of 5-HT release in SNr from WT (top) and TKO 
(bottom) mice in the presence and absence of 10 µM cocaine after 35 minutes.  Right 
Column:  Example responses of dopamine in striatal tissue from WT (top) and TKO (bottom) 
mice in the presence and absence of 2 µM cocaine after 35 minutes.   
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Figure 3.6  Dopamine and 5-HT release after 35 minutes of cocaine exposure relative to the 
predrug value.  Relative release of striatal dopamine in WT animals is significantly larger 
than that in TKO animals (p < 0.001, n = 4 for each genotype), whereas 5-HT release in SNr 
tissue (n = 7 for each genotype) is not significantly affected by cocaine in either genotype.   
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Figure 3.7  Effect of 2 µM cocaine on the Ca2+ dependence of dopamine release 
(normalized to release at 2.4 mM Ca2+) in striatal slices from WT and TKO mice.  A)  Ratio of 
release in the presence of cocaine to that in its absence as a function of external [Ca2+] for 
WT and TKO animals (n = 6, each genotype).  In slices from WT mice, cocaine significantly 
increases electrically stimulated dopamine release at all [Ca2+] below 2.4 mM, however, 
TKO animals are only facilitated at low levels of Ca2+.  (* p < 0.05, **p < 0.01, ***p < 0.001).  
B)  Relative [DA]max in TKO animals and WT animals as a function of extracellular Ca2+ in 
the presence of 2 µM cocaine.  Little difference in Ca2+ sensitivity is seen between the 
genotypes when cocaine is present (the curve shapes are similar).   
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The difference in Ca2+ sensitivity between WT and TKO animals shown in Figure 3.4 was 
abolished by 2 µM cocaine (Figure 3.7B).  Therefore, dopamine release from WT animals is 
preferentially facilitated in response to cocaine by a mechanism that is partially dependent 
on the extracellular [Ca2+]. 
Discussion 
 The comparison of dopamine and 5-HT release from WT mice and mice lacking all 
three synapsin genes reveals that synapsins play very different roles in nerve terminals 
employing these two biogenic amine neurotransmitters.  First, in the synapsin TKO mice, the 
release of dopamine evoked by electrical stimulation was almost twice as large as in WT 
mice.  This was true both in brain slices, where a stimulus was used to deplete the readily 
releasable dopamine pool and in vivo where the stimulation was sufficiently mild that 
continual release during both high and low frequency trains occurred.  In contrast, 5-HT 
release in the SNr was the same in the presence or absence of synapsins.  Cocaine blocked 
uptake of both 5-HT and dopamine, raising the apparent value of Km in both mouse 
genotypes, however it was only able to enhance the release of dopamine.  In addition, the 
enhancement of dopamine release was greater in WT animals than in TKO animals.  Thus, 
in the synapsin TKO mouse, dopamine release is larger and more sensitive to external 
calcium, but less susceptible to enhancement by cocaine.   
Synapsins Modulate Dopamine Release Dynamics 
Dopamine release was evaluated using intact animals and striatal brain slices.  Each 
preparation offers advantages and disadvantages.  The intact animal allows for remote 
stimulation of dopamine cell bodies using a variety of stimulation intensities and frequencies.  
However, the release that accompanies stimulus trains causes autoreceptor activation that 
can diminish dopamine release.  The slice preparation is more controlled because intense 
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single pulse stimuli can be used avoiding autoreceptor confounds (Kennedy et al., 1992).  
The slice preparation also provides an environment where drug and ion concentrations can 
be manipulated ad libitum.  Greater dopamine release was observed in both intact TKO 
mice and in striatal brain slices prepared from these mice confirming that the synapsins 
effect is mediated at the presynaptic terminal.  Although dopamine release was enhanced, 
its tissue content was the same in TKO and WT mice, clearly showing that deletion of 
synapsins caused a redistribution of releasable dopamine stores rather than a change in the 
stores themselves.  The increased release was not compensated by an alteration in uptake 
because the Vmax values for dopamine uptake were similar for both genotypes.   
Loss of synapsins has different effects on release of various transmitters.  At 
GABAergic synapses, loss of synapsins results in a decrease in GABA release evoked by 
single action potentials (Gitler et al., 2004).  Loss of synapsins decreases both the readily 
releasable vesicles near the active zone and those farther away, in the reserve GABAergic 
pool.  In contrast, synapsin deletion has no effect on glutamate release evoked by single 
action potentials (Gitler et al., 2004), but it does decrease the number of vesicles in the 
reserve pool only (Gitler et al., 2004).  In contrast, the loss of synapsins increases the 
release of catecholamines from adrenal chromaffin cells by increasing the number of 
exocytotic events, while the amount of catecholamine released per vesicle was unchanged, 
an effect reversed by expression of synapsin IIa (Villanueva et al., 2006). 
The greater dopamine release in TKO mice compared to WT mice does not seem to 
be the consequence of indirect effects mediated by GABA or glutamate activity since 
dopamine release was unchanged in the presence of CNQX and picrotoxin.  Thus, the 
neurotransmitter specific alterations in release from TKO mice are the result of a unique 
distribution of the synapsins in the biogenic amine neurotransmitter systems.  For example, 
the functional consequences of synapsin deletion for dopamine release appear similar to the 
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situation in chromaffin cells in that greater dopamine release is obtained (Figures 3.2A and 
3.3A); however, unlike chromaffin cells, dopamine terminals lack synapsin IIa (Bogen et al., 
2006).  Therefore, the most likely candidate for the differences in dopamine release between 
TKO and WT mice is synapsin III, an isoform that is found in the striatum (Pieribone et al., 
2002).  Mice with a deletion of synapsin III have an increased recycling pool of hippocampal 
synaptic vesicles (Feng et al., 2002).  Since neurotransmitter release measured in brain 
slices does not distinguish between the recycling and readily releasable dopamine pool, the 
same effect may explain our findings. 
Release studies done in the SNr show that there are no functional consequences on 
5-HT release as a result of synapsin deletion (Figure 3.1).  The lack of a synapsin effect in 
5-HT neurons is likely related to unique synapsin expression in these neurons.  In situ 
hybridization for synapsin I, II, and III mRNA shows that synapsin I is predominantly 
expressed synapsin gene in the SNr and dorsal raphe nucleus (Allen Institute for Brain 
Discovery).  The expression of synapsin II mRNA in the SNr is low and diffuse while 
synapsin III is not expressed at detectable levels.  The absence in the SNr of two candidates 
identified as negative regulators of biogenic amine release, synapsin II (Villanueva et al., 
2006) or synapsin III (this work), could explain the lack of synapsin regulation of 5-HT 
release.  It remains unclear why synapsin I does not negatively regulate release in 5-HT 
terminals.  Recent reports have indicated that the action of synapsin I on neurotransmitter 
release from motor synapses is only present at low levels of Ca2+ (0.5 mM) (Coleman and 
Bykhovskaia, 2009).  Therefore, it is possible that 5-HT release from these animals is 
altered but that the alterations were not apparent at the physiological levels of Ca2+ used in 
this experiment.  The difference between regulation of 5-HT and dopamine release may also 
originate from differences in their synaptic vesicles.  5-HT is mainly stored in large dense-
core vesicles (Nirenberg et al., 1995) whereas dopamine is primarily stored in small synaptic 
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vesicles (Nirenberg et al., 1997).  Accordingly, synapsins appear to associate most heavily 
with small synaptic vesicles in central nerve terminals (Fdez and Hilfiker, 2006).   
Synapsin Removal Alters Calcium Dynamics 
Calcium entry is required for stimulated dopamine release and may be necessary to 
liberate synapsin-dependent pool vesicles that supplement depleted releasable stores.  This 
mobilization is a slower process and occurs in the time between stimulations (Justice et al., 
1988).  Increasing extracellular calcium levels increases Ca2+ entry into the presynaptic 
terminals and subsequent accumulation of Ca2+ within the terminal (Nachshen and 
Sanchez-Armass, 1987) enhancing dopamine release.  Release at terminals from TKO mice 
was more sensitive to external Ca2+ than terminals from WT mice.  Even in the presence of 
low external Ca2+, dopamine release in the striatum of synapsin TKO animals was greater 
than in tissue from WT mice.  Quantitative analysis showed a higher KCa2+ for WT animals 
than TKO animals.  However, the similar Hill coefficients suggest that the same Ca2+-
dependent mechanisms that trigger release are operant in both genotypes.  The higher 
saturation value of dopamine release reached by TKO animals also indicates a larger pool 
of releasable vesicles. 
The Action of Cocaine Requires Synapsins 
 Dopamine release in tissue from WT mice undergoes greater enhancement by 
cocaine relative to TKO tissue.  Cocaine increases the extracellular dopamine concentration 
through at least two mechanisms.  The best understood is competitive blockade of the DAT 
inhibiting dopamine clearance (Jones et al., 1996; Wang et al., 1997; Uhl et al., 2002).  
However, cocaine also facilitates dopamine release from presynaptic terminals (Lee et al., 
2001), an effect that involves synapsin (Venton et al., 2006).  The facilitation of dopamine 
release by cocaine occurs in slices from WT animals and is significantly less in tissue from 
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synapsin TKO animals (Figure 3.6).  Since release in slices comes from the readily 
releasable pool, the facilitated release observed with cocaine in WT animals indicates it has 
altered the dynamics of this pool through a synapsin dependent pathway.  It is unclear at 
this point whether cocaine is acting directly on synapsin or inducing a cascade in the 
presynaptic terminal that involves synapsin dependent vesicles.  A synapsin independent 
pathway is necessary to explain the cocaine induced increase in dopamine release from 
TKO slices (Figure 3.6).  Repeated cocaine exposure has been shown to facilitate Ca2+ 
influx through l-type Ca2+ channels in the prefrontal cortex of rats (Nasif et al., 2005).  
However, a simple increase in overall Ca2+ influx would not explain the data in Figure 6 
because even at 5 mM extracellular Ca2+, the dopamine release in WT slices is not 
enhanced to the same degree as is seen in the presence of cocaine.  At low Ca2+ 
concentrations (when much less of the releasable pool is mobilized by the stimulation) 
cocaine still enhances dopamine release even in tissue devoid of synapsins, although to a 
lesser extent than seen in WT animals (Figure 3.7A).  The application of 2 µM cocaine 
alleviates the difference in Ca2+ sensitivity between TKO and WT animals evident by the 
similarity in the shape of their Ca2+ profiles (Figure 3.7B).  A combined effect of cocaine on 
calcium sensitivity and synapsin modulated dopamine release would explain the findings in 
both animals.  Dopamine release is an indirect measure of Ca2+ influx and its subsequent 
action; therefore, it is unclear how cocaine affects the Ca2+ sensitivity of release.  However, 
our findings are consistent with the observation that calcium channel knockout mice do not 
show an acute locomotor response to cocaine (Han et al., 2002).  
Cocaine is also a potent inhibitor of the serotonin transporter (Uhl et al., 2002; Uhl 
and Lin, 2003).  Measurements in the SNr confirm this action of cocaine by showing that the 
rate of uptake of 5-HT was lowered in the presence of cocaine (Figure 3.5).  However, 
unlike dopamine release, cocaine does not enhance 5-HT release (Figure 3.6).  
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Furthermore, there is no difference in cocaine sensitivity of 5-HT uptake between WT mice 
and synapsin TKO mice. These functional differences in the actions of cocaine on 
dopaminergic and serotonergic neurons may be indicative of the differences in the role of 
synapsins and their role in vesicular pool dynamics. 
The loss of synapsins causes neurotransmitter-specific changes in release from 
presynaptic terminals.  Loss of synapsins leads to a decrease in evoked GABA release, 
while release of glutamate and 5-HT is unaffected.  The release of dopamine is actually 
enhanced, a result that is likely due to removal of synapsin III.  Thus, synapsins appear to 
have dramatically different functions at presynaptic terminals that employ different 
neurotransmitters.  Future work will probe the molecular underpinnings of these differences 
in the contributions of synapsins to vesicle trafficking in these different types of presynaptic 
terminals.  
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Chapter 4 
Dopamine Uptake and Transporter Expression 
 
Introduction 
Dopamine is cleared from the extracellular space by uptake through a membrane 
bound dopamine transporter (DAT).  DAT belongs to a family of transporters including the 5-
HT transporter (SERT), and the norepinephrine transporter (NET) (Torres and Amara, 
2007).  This family of transporters is characterized by 12 transmembrane spanning domains 
and intracellular C-terminated and N-terminated domains.  The DAT co-transports dopamine 
along with 2 Na+ and 1 Cl- from the extracellular space into the intracellular compartment.  
Dopamine is a volume transmitter; therefore, the expression of DAT is not limited to 
neuronal synapses (Rice and Cragg, 2008).   
Extracellular dopamine concentrations are dependent on adequate DAT function; a 
property that can be altered by disease or drugs of abuse.  Several drugs of abuse (eg. 
cocaine, ampehetamine, methylphenidate, and methamphetamine) interact with the DAT to 
increase the extracellular dopamine concentration.  There is a large body of evidence 
suggesting that these increased dopamine concentrations are partly responsible for the 
addictive properties of these drugs (Sora et al., 2001; Uhl et al., 2002; Uhl and Lin, 2003).  
Dopamine transport blockers tend to reside in one of two categories with regards to their 
interaction with dopamine terminals.  Cocaine and cocaine like drugs increase extracellular 
dopamine by inhibiting the formation of a dopamine-DAT complex 
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(Jones et al., 1995; Uhl et al., 2002; Schramm-Sapyta et al., 2006).  This inhibition slows the 
re-uptake of dopamine and increases its extracellular residence time.  Cocaine itself has 
also been implicated as a facilitator of release, presumably by altering calcium sensitivity in 
dopamine neurons (White et al., 1998; Han et al., 2002; Schramm-Sapyta et al., 2006) 
(Chapter 3).  Amphetamines inhibit vesicular packaging through the vesicle monamine 
transporter (VMAT2) and invert the DAT, extruding cytosolic dopamine into the extracellular 
space (Sulzer et al., 2005; Wallace and Connell, 2008; Goodwin et al., 2009).  Cocaine 
actions on dopamine are said to be impulse dependent while amphetamines’ actions are 
not.  The study of DAT function is also important for disease state models in which 
dopamine transmission has been disrupted in some way.  The DAT is an attractive target 
when studying disease states related to hyper or hypo dopaminergia.  For example, 
attention deficit and hyperactivity disorder in humans is believed to be related to altered 
expression levels of DAT in the brain (Dougherty et al., 1999; Krause et al., 2006; Volkow et 
al., 2007). 
In this chapter, we describe the use of a novel transgenic mouse model to evaluate 
dopaminergic transmission in the face of altered DAT function.  Traditional studies of the 
dopamine transporter have relied on the presence of pharamacological agents to alter 
uptake.  More recently, transgenic mice expressing less DAT or no DAT at all have been 
used to elucidate the action of amphetamines, autoreceptor function, and behavioral 
phenotypes (Giros et al., 1996; Jones et al., 1998; Jones et al., 1999).  The novel transgenic 
mice described here express more DAT than their wild type counterparts, a very intriguing 
phenotype.  These mice were used to achieve a comprehensive understanding of how the 
amount of expressed DAT relates to dopamine uptake, extracellular dopamine 
concentrations, autoreceptor function, and amphetamine action at dopamine terminals.   
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Materials and Methods 
The electrochemical procedures used in this chapter have been explained in detail in 
Chapter 2.  The Southern blot analysis, Western blot analysis, and gold-silver staining have 
been explained in detail elsewhere (Salahpour et al., 2008).  The tissue levels of DA from 
the striatum of WT or DAT-Tg animals were evaluated using RP-HPLC with ECD as 
described previously (Wang et al., 1997).  Locomotor activity experiments were performed 
as described previously (Salahpour et al., 2008) using automated locomotor activity 
monitors (Accuscan Instruments).  Briefly, mice were initially placed for 60 min into the 
activity monitor chamber.  After this period of habituation, animals were injected (3 mg/kg of 
body weight i.p.) with vehicle or the drug, returned to the chamber, and the total distance 
covered monitored for additional 60 min after injection. 
Results 
Transgenic Modification of DAT Expression 
 Pronuclear injection of a DAT locus containing bacterial vector like that shown in 
Figure 4.1A was used to alter the expression of DAT in C57 BL/6 mice (Salahpour et al., 
2008).  The transfection of a WT animal containing two endogenous copies of the DAT gene 
yielded a DAT-Tg animal expressing 6 copies of the DAT gene (DAT-Tg (6)).  Southern blot 
analysis indicated a 3-fold increase in transporter DNA in DAT-Tg (6) animals relative to WT 
controls corresponding to the four additional gene copies (Figure 4.1B).  The increase in 
DNA was coincident with a 3-fold increase in DAT protein relative to WT animals as 
determined by Western blot analysis (Figure 4.1C).  To test the relationship between 
increased DAT protein and increased expression of transporters on the cell membrane, 
immunogold-silver staining was used to visualize DAT localization in electron micrographs 
(EMs) (Salahpour et al., 2008).  A qualitative increase in DAT can be easily seen by  
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Figure 4.1  Generation of DAT transgenic animals by pronuclear injection.  A) A 
representation of the bacterial vector used for the transfection.  B)  Southern blot analysis 
showing a significant (p < 0.001, n = 4 both genotypes) increase in DAT DNA, this increase 
in DNA corresponds to an additional four copies of the DAT gene.  C)  A Western blot 
confirming a 300 % increase in DAT protein levels in transgenic animals (p < 0.001, n = 5 
both genotypes).  Figure modified from Figure 1 of Salahpour et al. (2008).   
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comparing EMs from WT animals to those taken from DAT-Tg (6) animals (Figure 4.2).  DAT 
was expressed perisnyaptically on the plasma membrane and within intracellular 
compartments of dopamine terminals.  These data support a successful transfection 
technique in which the amount of membrane bound DAT can be increased by introducing 
more copies of the DAT gene. 
 This work will focus on the comparison of WT control animals with three different 
transgenic mouse models expressing different amounts of DAT.  The HET animal expresses 
only 1 copy of the DAT gene and was generated during the creation of the DAT KO mouse 
line (Giros et al., 1996).  The transfection of the HET animal using the pronuclear injection 
procedure described here was used to generate the DAT-Tg (5) animal.  Finally, transfection 
of a WT animal yielded a DAT-Tg animal expressing six copies previously defined as DAT-
Tg (6).  Therefore, HET animals have 1 DAT copy, WT animals have 2 DAT copies, DAT-Tg 
(5) animals have 5 DAT copies, and DAT-Tg (6) animals have 6 DAT copies.   
Variation of Vmax with Transporter Copy Number 
DAT expression changes the profile of stimulated dopamine release in striatal brain 
slices.  The DAT KO animal achieves a steady state dopamine concentration shortly after 
stimulation that does not change over the course of the recording (Figure 4.3).  The absence 
of appreciable clearance in the DAT KO animal confirms that uptake is the sole clearance 
mechanism of dopamine over the time course of these experiments as previously reported 
(Jones et al., 1999).  The expression of a single DAT gene creates a bi-phasic dopamine 
profile in which there is an immediate rise in the dopamine concentration after stimulation 
followed by dopamine uptake (Figure 4.3).  Increased expression of DAT from 1 copy to 5 
copies changes this profile by making the peak shorter in time and smaller in size.  To 
evaluate this phenomenon, dopamine uptake in brain slices containing the caudate putamen  
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Figure 4.2  Immunogold-silver staining of the dorosolateral striatum (scale bar: 500 nm).  
Asterisks denote immunoreactive axons and the white arrow shows a synapse with a 
medium spiny neuron.  Black arrows indicate cytoplasmic gold particles, all other gold 
particles are associated with the plasma membrane.  There is a larger amount of membrane 
associated DAT in transgenic animals (Bottom Panel) compared to WT animals (Top 
Panels).  Localization indicates perisynaptic DAT reactivity.  Figure adapted from Figure 3 in 
Salahpour et al. (2008).  
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Figure 4.3  The rate of uptake changes with the expression level of the DAT gene.  
Stimulated dopamine release in the caudate putamen of mice expressing 0, 1, and 5 copies 
of the DAT gene.  The animal without expressed DAT is unable to clear dopamine after it is 
released.  As more DAT is expressed, the rate of dopamine uptake increases manifested by 
a thinner and shorter peak in the trace from a 5 copy animal vs. the trace from a 1 copy 
animal. 
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of DAT-Tg (6) mice was measured using either FSCV or amperometry and compared to the 
uptake of WT animals (Figure 4.4). 
In constant-potential amperometry, the electrode is held at a fixed potential sufficient 
to oxidize dopamine when it contacts the electrode surface (Venton et al., 2002).  When 
release is evoked by a single pulse stimulation in tissue from WT animals, there was an 
almost immediate rise in dopamine followed by a decay to baseline (Figure 4.4A).  In striatal 
tissue from transgenic animals the amplitude of release was smaller and the decay faster 
than in WT tissue.  The initial descending slope taken from [DA]max to ½ [DA]max was used as 
the Vmax value.  The Vmax value for WT animals and DAT-Tg (6) animals was compared to 
quantify the apparent difference in uptake rate.  The Vmax ratio of DAT-Tg (6) to WT (n = 5, 
each genotype) was found to be 1.62 for amperometry (Figure 4.4A).   
Dopamine release and uptake was also evaluated with FSCV in which voltage scans 
sufficient to oxidize dopamine were recorded at periodic intervals, every 16.7 ms in this 
case.  The current at the peak potential for dopamine oxidation is taken as a measure of the 
dopamine concentration (Baur et al., 1988).  Again, a single pulse electrical stimulation was 
used to evoke dopamine release in striatal brain slices from WT animals and DAT-Tg (6) 
animals.  Release measured by FSCV was lower and the disappearance was faster in DAT-
Tg (6) striatal brain slices than WT striatal brain slices (Figure 4.4B).  The responses are 
qualitatively similar to the amperometry data (compare Figures 4.4A and 4.4B). 
To evaluate the kinetics of dopamine uptake using FSCV measurements, traces 
were deconvoluted to account for the temporal distortion due to dopamine adsorption and 
evaluated with a using simplex non-linear regression model (Figure 4.4B, solid traces).  The 
Vmax values obtained from the examples in Figure 4.4B were 5.0 μM/s for WT and 7.2 µM/s 
for DAT-Tg (6); the overlays clearly indicate a reasonable fit.  The Vmax ratio of DAT-Tg (6) to  
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Figure 4.4  The rate of uptake in WT and DAT-Tg (6) animals measured with amperometry 
and FSCV.  A) Amperometric recordings of stimulated dopamine release in WT and DAT-Tg 
(6) animal.  The slope of the curve was taken from [DA]max to ½ [DA]max  and compared for 
both gentoypes, the DAT-Tg (6) / WT ratio was determined to be 1.62 (n = 5 each 
genotype).  B)  Stimulated dopamine release as measured by FSCV in striatal brain slices 
from WT and DAT-Tg (6) animals.  The solid line is the non-linear model used to determine 
Vmax values from FSCV data.  Based on the model curve, the Vmax values for these traces 
were 5.0 μM/s for WT and 7.2 µM/s for DAT-Tg (6), a ratio of 1.44.   
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WT was found to be 1.44 for FSCV modeling (n = 5, each genotype), quite similar to the 
ratio obtained by amperometry.  The similarity in the Vmax ratio between amperometric 
recordings and FSCV recordings indicates that FSCV with deconvolution has sufficient 
temporal resolution to monitor uptake in animals overexpressing the dopamine transporter.  
A more complete discussion of how adsorptive delay affects dopamine uptake 
measurements can be found in Chapter 8. 
The Vmax of dopamine uptake was measured using simplex non-linear regression of 
stimulated dopamine release for HET, WT, DAT-Tg (5), and DAT-Tg (6) animals (Figure 
4.5A, n = 5 for all four genotypes).  An increase in the expression level of DAT led to a 
significant (p < 0.001 for DAT-Tg (5) and DAT-Tg (6)) increase in maximal uptake rate while 
a reduction in DAT expression significantly (p < 0.01) decreased uptake in HET animals.  
The increase in uptake rate seen in DAT-Tg (6) animals was independent of a change in the 
binding affinity of dopamine for the transporter as indicated by the Km value (Figure 4.5B).  
The maximal uptake rate does not scale proportionally with number of transporter copies 
indicating that there is not a direct relationship between the number of gene copies and the 
amount of transporter participating in dopamine uptake (Salahpour et al., 2008). 
Increased Uptake Reduces Extracellular Dopamine Levels 
Electrically evoked dopamine release was monitored using FSCV in striatal brain 
slices to determine the relationship between the number of transporters and maximal 
dopamine release (Figure 4.6).  Changing the expression of DAT significantly alters the 
[DA]max achieved by local electrical stimulation in striatal brain slices.  HET animals release 
significantly (p < 0.01, n= 5) more dopamine than WT animals while DAT-Tg (5) and DAT-Tg 
(6) animals each release significantly less dopamine (p < 0.001, n = 5 both genotypes) than 
WT animals (Figure 4.6).  To assess if these release differences were due to differences in  
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Figure 4.5  Uptake rate constants measured in WT and DAT-Tg animals.  A)  There is a 
significant (*** p < 0.001, n = 5, one way anova) increase in Vmax when additional copies of 
the dopamine transporter are expressed (DAT-Tg animals) when compared to WT animals.  
A decrease in the expression of the DAT significantly (** p < 0.01, n = 5, one way anova) 
decreases Vmax in HET animals.  B)  There is no difference in the equilibrium binding affinity 
(Km) of dopamine at the transporter (p > 0.05, n = 5) in DAT-Tg (6) animals compared to WT 
animals.  
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Figure 4.6  The [DA]max measured at the electrode is altered in mice over expressing the 
DAT.  When compared to WT animals, DAT-Tg (6) and DAT-Tg (5) animals have a 
significantly lower [DA]max  (*** p < 0.001, n = 5, one way anova) and HET animals have a 
significantly higher [DA]max  (** p < 0.01, n = 5, one way anova).  
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uptake rate, release in HET, WT, and DAT-Tg (5) animals was compared in the presence 
and absence of uptake blockade (Figure 4.7, n = 4 all genotypes).  In the absence of uptake 
blockade, the measured maximal dopamine signal decreased from 2.13 μM for HET to 0.67 
µM for DAT-Tg (5) animals (Figure 4.7A).  However, in the presence of the uptake inhibitor 
PTT the electrically evoked dopamine signal was approximately 3.50 µM for all three animal 
genotypes (Figure 4.7B).  The data shown in the presence of uptake blockade agrees with 
the total content analysis which shows that the three genotypes studied have the same 
amount of total dopamine in striatal tissue, about 12 µg/g (n = 12, each phenotype).  Taken 
together, these data clearly demonstrate that the DAT expression level is critical for 
spatiotemporal control of dopamine. 
DAT Overexpression Does Not Affect Autoreceptor Efficacy 
 The efficacy of D2-autoreceptors on dopamine release in the caudate putamen of 
mice overexpressing the dopamine transporter was compared to WT mice by application of 
the D2-agonist, quinelorane.  Measurements were taken in striatal brain slices in response to 
a single pulse electrical stimulation.  The effect of autoreceptor agonism on the maximal 
dopamine release of WT mice and DAT-Tg (5) was evaluated using FSCV.  A dose 
response curve to ascending concentrations of quinelorane (0.5, 1, 2.5, 5, 10, 25, 50, 100, 
and 250 nM) was generated for WT animals and DAT-Tg (5) animals.  The maximal 
dopamine release at each drug concentration was normalized to the predrug release value 
and plotted against the log of the drug concentration (Figure 4.8).  There is no statistical 
difference (p > 0.05) in the response to quinelorane for DAT-Tg (5) animals compared to WT 
animals at any concentration of the D2-autoreceptor agonist (n = 5, each phenotype).  The 
dose response curves were also fit to a sigmoidal (variable slope) regression to calculate 
EC50 values for quinelorane for each genotype.  The EC50 values for quinelorane in WT and 
DAT-Tg (5) animals were 4.9 ± 1.1 nM and 4.3 ± 1.1 nM respectively, not statistically  
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Figure 4.7  Release differences are abolished by uptake blockade. A)  The amount of 
dopamine released (as measured at the electrode) for a single pulse stimulation (n = 4, each 
genotype) decreases with increasing DAT expression. B)  The application of DAT inhibitor 
PTT abolishes the perceived difference in dopamine release (n = 4, each gentoype) when 
evoked by the same single pulse stimulation.   
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Figure 4.8  Autoreceptor efficacy in DAT-Tg (5) animals.  Application of ascending 
concentrations of D2-agonist quinelorane causes a decrease in stimulated dopamine 
release.  There is no significant difference (p > 0.05, n = 5) in the efficacy of quinelorane in 
DAT-Tg (5) animals compared to WT animals.  The EC50 of quinelorane in WT and DAT-Tg 
animals were 4.9 ± 1.1 nM and 4.3 ± 1.1 nM respectively.  
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different (p > 0.05).  These values are similar to values found in the literature for quinelorane 
at D2-autoreceptors but much higher than the EC50 of the D2 agonist quinpirole (Bates et al., 
1991; Mercier et al., 2001).  
Behavioral Phenotypes of DAT Transgenic Animals 
 Injection of 3 mg/kg amphetamine to WT animals and DAT-Tg (5) animals has a 
dramatically different effect on locomotion (Figure 4.9).  The basal movement level taken for 
60 minutes prior to injection was the same for WT mice and DAT-Tg (5) animals (Figure 
4.9).  Upon injection of 3 mg/kg amphetamine i.p. the DAT-Tg (5) animals undergo greater 
behavioral activation than WT animals for the first 30 minutes after drug.  After 30 minutes, 
both genotypes show a similar increase in behavioral activation over baseline. 
 The behavioral activation seen in DAT-Tg animals is not due to a difference in 
dopamine reverse transport caused by amphetamine.  The ability of amphetamine to induce 
reverse transport in WT animals and DAT-Tg (5) animals was evaluated using FSCV in 
striatal brain slices.  Vesicular dopamine was first depleted by application of 10 µM 
tetrabenazine, a VMAT2 inhibitor that does not cause reverse transport alone (Jones et al., 
1998).  The application of tetrabenazine eliminates stimulated dopamine release after 1 
hour.  During this time period, presynaptic dopamine was protected from breakdown by 
monamine oxidase (MAO) using 20 µM pargyline, an MAO inhibitor (Rice et al., 1997).  
Application of 20 μM amphetamine to the superfusion buffer after vesicular depletion results 
in a dramatic rise in the amount of basal dopamine as measured by a shift in the FSCV 
background current (Figure 4.10).  The baseline rise seen after depletion mimics that seen 
with direct application of amphetamine to striatal brain slices (Jones et al., 1998).  Cyclic 
voltammograms taken at the ½ [DA]max for WT and DAT-Tg (5) slices confirm that the 
measured signal increase is dopamine.  The rate of reverse transport is the same in WT and  
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Figure 4.9  Behavioral activation induced by amphetamine injection.  The distance traveled 
shown per 5 minute interval for WT and DAT-Tg (5) mice, there is no difference in 
locomotion prior to amphetamine injection.  An ip injection of 3 mg/kg amphetamine causes 
greater behavioral activation in DAT-Tg (5) animals compared to WT control animals for the 
first 30 minutes.  After 30 minutes, DAT-Tg (5) animals are still facilitated to a greater extent 
than WT animals, a level above baseline.   
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Figure 4.10  Basal dopamine concentration changes due to amphetamine application.  
Vesicular dopamine stores were depleted by application of VMAT2 inhibitor tetrabenazine 
(10 µM) and protected by enzymatic degradation by 20 µM pargyline (an MAOI).  Application 
of 20 µM amphetamine facilitated a rise in the basal dopamine concentrations to 4.5 µM 
dopamine for both genotypes with 50 % [DA]max reached 2 ½ minutes after onset (data 
reduced to 10 second intervals for clarity).  Cyclic voltammograms taken at the 50 % of 
[DA]max confirm the measured substance is dopamine.  No differences (n = 5, both 
gentoypes) were seen in the rise time or [DA]max between DAT-Tg (5) and WT animals.   
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DAT-Tg animals with the ½ [DA]max occurring ~2 minutes after onset (which is approximately 
5 ½ minutes after drug application).  In addition, the amount of dopamine released is not 
significantly different (p > 0.05) in slices from WT and DAT-Tg animals being 4.4 ± 0.77 μM 
and 4.6 ± 0.49 μM respectively.  The magnitude and time course of the shifts in the basal 
dopamine concentration as a result of amphetamine application does not depend on the 
number of dopamine transporters on the membrane surface when tetrabenazine has been 
used to deplete vesicular stores.   
Discussion 
DAT Expression and Dopamine Uptake 
 The relationship between the amount of expressed dopamine transporter and the 
rate of dopamine uptake has been described using transgenic mouse models.  The 
pronuclear injection of the DAT locus facilitates the integration of four additional DAT gene 
copies and a 300 % increase in DAT protein (Figure 4.1).  Increased protein expression 
does not linearly translate to increased membrane bound transporter; therefore, 
immunogold-silver staining was used to asses the compartmentalized expression of DAT in 
striatal tissue (Figure 4.2).  DAT expression was shown to be increased on the membrane 
as well as within intracellular compartments in DAT-Tg (6) animals. 
Stimulated dopamine release in the caudate putamen is bi-phasic consisting of an 
immediate rise in dopamine concentration followed by clearance of dopamine through DAT.  
As Figure 4.3 shows, the shape of stimulated dopamine release in striatal brain slices is 
dependent on the amount of transporter available.  Of particular interest is the lack of any 
clearance in a DAT KO animal supporting the assertion that DAT is the primary clearance 
mechanism for dopamine (Garris and Wightman, 1995; Giros et al., 1996).  Increased 
expression of DAT in WT animals increases the rate of dopamine uptake in striatal brain 
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slices after stimulated release as indicated by two electrochemical techniques: FSCV and 
amperometry (Figure 4.4).  Simplex modeling of FSCV traces collected from three different 
transgenic models supports the assertion made by Michaelis-Menten kinetic theory: Vmax 
scales with the amount of expressed dopamine transporter.  Figure 4.5A shows compiled 
Vmax values from animals expressing a range of transporter amounts.  Increased transporter 
causes a significant increase in Vmax while a decrease in transporter causes as significant 
decrease in the Vmax for dopamine uptake.  The increased maximal uptake rate documented 
in DAT-Tg (6) animals (Salahpour et al., 2008) is independent of a change in the binding 
affinity of dopamine for DAT with both animals showing Km (Figure 4.5B)(Salahpour et al., 
2008) values similar to those reported previously in rats (Near et al., 1988).  The increased 
Vmax for DAT-Tg animals (about 60 %) is not proportional to the 250 % increase in 
membrane associated DAT protein reported by Salahpour et al. (2008).  It is much closer to 
the reported 30 % enhancement in synaptic plasma membrane associated DAT in these 
animals (Salahpour et al., 2008).  These data indicate that there is a component of DAT 
trafficking that limits the amount of membrane associated protein available to participate in 
uptake.  A multitude of proteins have been shown to interact with the DAT (Torres, 2006) 
some of which may have altered expression levels in DAT-Tg animals.  Increasing the 
expression of proteins designed to limit DAT surface expression would decrease the impact 
of such a drastic change in transporter protein levels during development.  This ceiling effect 
on DAT membrane expression may also explain why there is little difference in the uptake 
rates of DAT-Tg (5) and DAT-Tg (6) animals even though a very large difference in uptake is 
seen between HET and WT animals (Figure 4.5A). 
DAT Expression and Dopamine Levels 
 The amount of dopamine incident on synaptic targets is a balance between release 
and uptake events.  Dopamine is thought to act through volume transmission (Rice and 
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Cragg, 2008); an assertion supported by perisynaptic expression of DAT in the dorsolateral 
striatum (Figure 4.2).  We show a significant decrease in stimulated dopamine release from 
striatal brain slices of DAT-Tg (5) and DAT-Tg (6) animals compared to WT animals; a 
reduction coincident with lower extracellular dopamine levels as determined by in vivo 
microdialysis (Salahpour et al., 2008).  Conversely, an increase in [DA]max is seen in HET 
animals similar to the signal increase characteristic of pharmacological uptake inhibition 
(Jones et al., 1995; Lee et al., 2001).  There is no clear indication whether the differences in 
[DA]max found in DAT-Tg animals are due solely to differences in uptake or if they have a 
release component.  The DAT-Tg (6) animals have neurodegeneration indicated by a lower 
striatal dopamine total content value relative to WT animals (6 µg/g for DAT-Tg (6) vs. 12 
µg/g for WT).  However, there must be some contribution from uptake to the differences in 
stimulated [DA]max because no total content abnormalities were documented between WT, 
HET, and DAT-Tg (5) animals.  The ability of the uptake blocker PTT to normalize the 
release of WT, HET, and DAT-Tg (5) animals supports the hypothesis that the uptake rate in 
part controls the amount of dopamine able to contact the electrode.  Unfortunately, the PTT 
data does not prove this effect because it is a cocaine analog and cocaine has been shown 
to alter dopamine release properties (Chapter 3) (Venton et al., 2006).  These data clearly 
demonstrate how intertwined dopamine release and uptake events are when it relates to 
extracellular dopamine concentrations. 
 The presynaptic D2 autoreceptor is coupled to and a modulator of the DAT (Ralph et 
al., 2001; Bertolino et al., 2009).  Mice lacking the D2 autoreceptor show decreased DAT 
function in the dorsolateral striatum (Dickinson et al., 1999).  Conversely, mice lacking the 
DAT lack D2 modulation of stimulated dopamine release (Jones et al., 1999).  We 
investigated any release regulating autoreceptor changes in mice that overexpress the DAT 
using the D2 agonist quinelorane to modulate stimulated dopamine release.  Dopamine 
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release is an indirect measure of autoreceptor function; however, it is the most pertinent in 
the context of a study on release and uptake in these animals.  No difference in 
autoreceptor efficacy was documented in DAT-Tg (5) animals relative to WT animals.  The 
hypodopaminergic state of DAT-Tg animals has been shown to affect the expression and 
efficacy of post-synaptic D2 receptors in the striatum (Ghisi et al., 2009).  Our data suggests 
that the receptor change does not translate to the presynaptic terminal or that presynaptic 
D2 receptor modifications are not affecting stimulated dopamine release to a different degree 
than WT mice.   
Amphetamine Action on Dopamine Terminals 
 Behavioral activation due to amphetamine is altered in mice overexpressing the 
dopamine transporter.  Salahpour et al. (2008) found DAT-Tg (6) mice experienced greater 
behavioral activation when exposed to amphetamine; a result not duplicated with cocaine, 
GBR-12909, or methylphenidate.  Amphetamine caused a 400 % increase over basal 
dopamine levels in DAT-Tg (6) animals compared with a 200 % increase in WT animals 
(Salahpour et al., 2008).  These data are consistent with the theory that many amphetamine 
effects are dependent on the expression level of DAT.  Accordingly, amphetamine is unable 
to facilitate dopamine reverse transport in DAT KO animals (Jones et al., 1998).  A second 
behavioral study was done in DAT-Tg (5) and WT animals to rule out the contribution of 
neuronal degeneration on the behavioral activation in DAT-Tg (6) animals.  After a 60 
minute habituation period, the introduction of 3 mg/kg amphetamine causes a drastic 
increase in the movement of DAT-Tg (5) animals over that seen in WT animals (Figure 4.9).  
This behavioral activation is independent of a change in the rate or magnitude of reverse 
transport in DAT-Tg (5) when cytosolic dopamine levels have first been increased by 
tetrabenazine (Figure 4.10).  Therefore, a pathway independent of reverse transport but 
related to DAT expression is causing the increase in basal dopamine levels.  A possible 
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mechanism may be related to the accumulation of presynaptic amphetamine through DAT.  
Increased transporter expression would facilitate greater amphetamine accumulation within 
the presynaptic terminal because amphetamine can utilize the transporter to enter the 
presynaptic terminal (Jones et al., 1998).  Increased amphetamine accumulation will 
enhance VMAT2 blockade and end point inhibition of tyrosine hydroxylase (Kehr et al., 
1977; Wallace and Connell, 2008) in DAT-Tg (5) animals without altering the rate of reverse 
transport. 
Our experiments do not rule out a post-synaptic component to the amphetamine 
effect; D1 and D2 receptors are upregulated in DAT-Tg mice (Ghisi et al., 2009).  A 
postsynaptic pathway would be affected equally by increased extracellular dopamine levels.  
Traditional uptake blockers are able to increase extracellular dopamine but not to a level 
high enough to cause preferential activation in DAT-Tg animals.  Amphetamine must be 
able to increase extracellular dopamine tone to a greater extent than these drugs.  Cocaine, 
GBR, and methylphenidate are impulse dependent drugs meaning they require continued 
vesicular release to have an effect.  As these drugs begin to act, they increase extracellular 
dopamine which inhibits further dopamine release by acting on autoreceptors (Kita et al., 
2007).  The negative feed back loop of the autoreceptors would put a ceiling on the 
effectiveness of these drugs at increasing dopamine tone.  Amphetamine is able to increase 
dopamine tone to a greater extent by utilizing reverse transport through the DAT, an impulse 
flow independent pathway unaffected by autoreceptor modulation.  It is hypothesized that 
amphetamine would be able to induce a larger increase in dopamine tone in both animals.  
Increased dopamine tone would act on the increased number of D1 and D2 receptors in 
DAT-Tg (5) animals causing behavioral activation.   
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Chapter 5 
Mitochondrial Proteins and Dopamine Release 
 
Introduction  
Uncoupling protein 2 (UCP2) belongs to a family of five mitochondrial uncoupling 
proteins believed to regulate adenosine triphosphate (ATP) formation.  UCPs are believed to 
differ substantially in location and function in comparison with UCP1 (expressed solely in 
brown adipose tissue), the best understood uncoupling protein.  UCP2 is expressed at 
relatively low levels in the brain when compared to other UCPs such as UCP4 (Alan et al., 
2009), however it is believed to play a vital role in local thermogenesis, Ca2+ regulation, ATP 
formation, and superoxide protection within nerve terminals (Zhang et al., 2001; Horvath et 
al., 2003).  Figure 5.1 shows the inner mitochondrial membrane through which ATP is 
generated in nerve terminals.  Protons generated by the electron-transport chain 
accumulate in the intermembrane space, altering the inner membrane potential.  As protons 
build up in this space they can move back across the inner mitochondrial membrane through 
ATP synthase (Figure 5.1), a process that generates ATP.  UCP2 is believed to provide an 
alternate route that allows protons to pass into the inner mitochondrial space and bypass 
ATP synthase, effectively uncoupling the electron-transport chain from ATP synthesis 
(Figure 5.1) (Horvath et al., 2003).  A byproduct of this uncoupling is a decrease in formation 
of radical oxygen species that are generated when electrons leak from the electron-transport 
chain (Negre-Salvayre et al., 1997), a natural but undesirable process.  Some believe that 
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Figure 5.1  Uncoupling Protein 2 (UCP2) is expressed on the inner mitochondrial 
membrane.  The electron transport chain establishes a proton (H+) gradient within the 
mitochondria.  Protons travel along their concentration gradient through ATP synthase 
generating ATP.  UCP2 allows protons to flow into the mitochondrial matrix without 
generating ATP.   
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UCP2 regulation of ATP generation only occurs in response to oxidative stress to help limit 
cell damage from radical oxygen species (Echtay, 2007).  However, other studies have 
shown that UCP2 accounts for 50 % of the nominal proton leak in resting cells and that 
animals lacking UCP2 have increased ATP levels compared to WT animals (Krauss et al., 
2002).   
A large number of processes in the nerve terminal are dependent on the energy 
state of the neuron.  For example, vesicle packaging and recycling, calcium buffering, and 
vesicle mobility are all ATP-dependent processes (Burgoyne and Morgan, 2003; Chen et al., 
2003; Stokes and Green, 2003).  No firm hypothesis has been generated as to which 
aspects of neuronal transmission will be affected by knocking out UCP2 (Horvath et al., 
2003).  However, clues come from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), an 
agent that specifically causes mitochondrial disruption in dopaminergic neurons.  MPTP 
enters dopamine terminals by uptake through the dopamine transporter (DAT) where it is 
metabolized to 1-methyl-4-phenylpyridinium (MPP+) by monoamine oxidase B (MAOB).  
MPP+ passes through the mitochondrial membrane where it interferes with complex I in the 
electron-transport chain enhancing electron leakage and formation of radical oxygen 
species (Sayre, 1989; Mizuno et al., 1990).  Accumulated free radical oxygen species cause 
oxidative damage, eventually leading to cell death.  It remains unclear exactly how UCP2, 
endogenously expressed in nigrostriatal dopamine cell bodies (Figure 5.2) (Conti et al., 
2005), may be related to this toxicity.  However, overexpression of UCP2 and UCP4 have 
been shown to decrease MPTP induced neurotoxicity in dopamine neurons (Conti et al., 
2005; Chu et al., 2009), presumably by alleviating the free radical buildup associated with 
MPP+ action in mitochondria.  The question remains: How does the deletion of UCP2 affect 
the normal function of the nigrostriatal dopamine pathway? 
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Figure 5.2  In situ hydridization in the substantia nigra pars compacta.  Slices (25 µm in 
thickness) were labeled using a nuclear stain and a ribosomal probe.  Cell bodies are 
visualized in blue (black arrows).  A 35S-labeled riboprobe as described in Parton et al. 
(2007) was used to visualize locations of UCP2 expression (black dots).  There is co-
localization between dopamine neuron cell bodies and UCP2.  Additionally, UCP2 appears 
to be expressed in some of the terminal regions surrounding the cell bodies.  The terminals 
innervating dopamine cell bodies in the compacta are primarily glutamate, GABA, and 5-HT.  
Scale bar 20 µm.  
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This chapter focuses on the role played by UCP2 in the modulation of dopamine 
release in caudate putamen brain slices.  Electrically stimulated dopamine release in striatal 
brain slices of UCP2 KO animals was found to be enhanced compared to WT animals and 
coincided with an increase in the maximal rate of dopamine uptake (Vmax).  Application of the 
UCP2 cross-linker genipin was used to show that the effects of knocking out UCP2 are not 
acute (less than 2 hours), but are most likely due to adaptive changes within the terminal. 
Materials and Methods 
 A full description of techniques used in this chapter can be found in Chapter 2.  In 
situ hybridization of dopaminergic neurons in the substantia nigra compacta was performed 
as previously described (Parton et al., 2007).  
Disclaimer 
 This chapter shows data taken as part of a collaboration with the lab of Dr. Brad 
Lowell at Beth Israel Deaconess Hospital in Boston, Massachusetts.  My direct contact 
person at that lab provided me with the genetic identities of all mice used in this study.  This 
contact was recently removed from his/her position due to academic misconduct in regards 
to the study on UCP2 and how its expression is altered in obese animals.  The genetic 
identities of the animals provided to me have in one form or another been confirmed by the 
Lowell lab as being correct. Therefore, I stand behind the results shown here and the 
conclusions drawn from them.  Unfortunately, many of the hypotheses tested in this chapter 
were based on data that is now in question.  To this end, this chapter will only show data 
that has been confirmed to be accurate and will serve as a preliminary discussion of 
possible mechanisms.   
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Results 
UCP2 Expression in the Substantia Nigra pars Compacta 
 To verify literature reports that UCP2 is present in the mitochondrial membrane of 
dopamine neurons, in situ hydridization was used.  In situ hybridization of UCP2 mRNA was 
performed on brain slices containing the substantia nigra pars compacta.  Slices (25 µm 
thickness) were taken containing dopamine midbrain neurons and stained to visualize cell 
bodies in blue, several of which are denoted by black arrows (Figure 5.2).  The location of 
UCP2 mRNA was visualized using 35S-labeled riboprobes (black dots).  There is UCP2 
mRNA expression in the dopamine cell bodies of the zona compacta of the substantia nigra. 
Stimulated Neurotransmitter Release in Mouse Brain Slices 
 Release and uptake of dopamine was evaluated in striatal brain slices containing the 
caudate putamen.  Stimulated dopamine release was measured at several locations within 
the caudate putamen using FSCV.  Dopamine release evoked by a single stimulus pulse in 
UCP2 KO animals was significantly larger (p < 0.01) than evoked dopamine release from 
WT slices (Figure 5.3A, n = 10 both genotypes).  To determine if there was also a change in 
dopamine uptake, deconvolution and simplex modeling of the dopamine concentration 
traces were used.  The Vmax of dopamine uptake in the striatum of UCP2 KO animals is 
significantly larger (p < 0.01, n =10 both genotypes) than that found in WT animals (Figure 
5.4). 
 5-HT release in brain slices containing the substantia nigra pars reticulata was also 
evaluated using electrical stimulation and FSCV.  The 5-HT released in response to a 20 
pulse 100 Hz stimulation was not significantly altered in UCP2 KO mice compared to WT 
mice (Figure 5.3B) (p > 0.05, n = 10 both gentoypes).  Uptake rates were also unchanged in 
this preparation (data not shown). 
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Figure 5.3  UCP2 deficiency affects striatal dopamine release but not stimulated 5-HT 
release in the substantia nigra.  A) Stimulated dopamine release in the caudate putamen of 
UCP2 KO mice is significantly enhanced relative to WT animals (** p < 0.01, one-way 
anova, n = 10 both genotypes).  B) There is no significant difference in stimulated 5-HT 
release between WT animals or UCP2 KO animals (p > 0.05, n ≥ 9, both genotypes). 
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Figure 5.4  The maximal rate of dopamine clearance is altered in UCP2 KO mice.  Temporal 
deconvolution and simplex modeling were used to extract a Vmax value from the dopamine 
traces taken in the caudate putamen.  As seen with dopamine release, the Vmax of dopamine 
uptake is significantly enhanced in UCP2 KO mice compared to WT animals (**, p < 0.01, 
one-way anova, n = 5 both genotypes).   
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Figure 5.5  Genipin modulation of dopamine release and uptake in mouse brain slices.  The 
addition of 20 µM genipin to striatal brain slices for 35 minutes does not significantly (p > 
0.05, n = 5 both genotypes) alter [DA]max or Vmax in WT mice when compared to UCP2 KO 
mice.  In this experiment, the UCP2 KO mouse is the control animal because UCP2 KO 
mice are insensitive to genipin.   
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Genipin Modulation of Dopamine Release 
 Genipin, a UCP2 cross-linker (Zhou et al., 2009), was used in an attempt to acutely 
modulate dopamine release in striatal brain slices.  A 20 µM dose of genipin was applied to 
striatal brain slices for 35 minutes, and then stimulated dopamine release was measured at 
three locations within the caudate.  The dose and time frame used was previously shown to 
be sufficient to alter ATP levels in striatal synaptosomes (Lowell Lab, unpublished) and alter 
glucose sensing in pancreatic slices (Parton et al., 2007).  Figure 5.5 shows the ratiometric 
change in [DA]max and Vmax for WT animals and UCP2 KO animals (n = 5, both genotypes).  
For these experiments, the UCP2 KO animal was used as a negative control because it 
should be insensitive to the effects of genipin.  The application of 20 µM genipin did not 
significantly alter (p > 0.05, single value t-test) stimulated release or uptake of striatal 
dopamine in brain slices.   
Discussion 
 The family of uncoupling proteins to which UCP2 belongs has numerous functions 
including Ca2+ modulation, mediation of reactive oxygen species (ROS), and regulation of 
ATP formation.  It is difficult to predict what effect, if any, the total removal of UCP2 will have 
on dopamine dynamics.   
 The hypothesis that UCP2 is primarily protective by diminishing ROS-induced 
damage in dopamine cell bodies would imply that UCP2 KO mice should experience 
dopamine cell degeneration over time.  In fact, UCP2 has been shown to decrease the 
oxidative stress in different types of murine tissue during the aging process (Andrews and 
Horvath, 2009).  Damage-induced cell loss in the substantia nigra should lead to decreased 
dopamine release in the caudate putamen.  However, the literature relating UCP2 
expression to dopamine cell death is minimal.  Several studies have shown that the 
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overexpression of UCP2 allows dopamine neurons to better resist MPTP toxicity (Conti et 
al., 2005; Chu et al., 2009).  Overexpression of UCP2 decreased ROS formation in the 
substantia nigra, while the removal of UCP2 had the opposite effect.  Larger MPTP toxicity 
was documented in UCP2 KO animals compared to WT animals and was coincident with 
decreased mitochondrial number in substantia nigra cell bodies (Andrews et al., 2005).  
These studies indicate quite strongly that a primary function of UCP2 is the protection of 
dopamine neurons from oxidative stress (Horvath et al., 2003).  However, their conclusions 
rely heavily on a drug-induced Parkinsonian model.  These MPTP-induced toxicity studies 
are problematic because the rate of MPP+ (the metabolite responsible for cell death in this 
model) uptake into the mitochondria is related to the mitochondrial membrane potential 
(Scotcher et al., 1991; Chen et al., 2005; Kim et al., 2006).  UCP2 negatively modulates 
inner membrane potential (Horvath et al., 2003).  UCP2 KO animals should uptake more 
MPP+ than WT animals causing more damage and presumably greater cell death.  
Therefore, the relationship between cell viability and UCP2 cannot be accurately tested 
using MPTP and cannot be considered an indicator of UCP2 function during nominal 
dopamine action. 
 The transgenic removal of UCP2 causes an increase in stimulated dopamine release 
as measured by FSCV in brain slices (Figure 5.3A).  Release facilitation is preferential to 
dopamine neurons, as stimulated 5-HT release in substantia nigra brain slices remains 
unaffected (Figure 5.3B).  Increased dopamine release is not modulated acutely by altering 
UCP2 function over short times (2-3 hours), implying that a long term or adaptive 
mechanism is most likely.  Total dopamine content analysis by HPLC showed no difference 
in the amount of striatal dopamine between WT and UCP2 KO animals (Table 6.1), and no 
changes in DAT binding have been realized between genotypes (data not shown) (Andrews 
et al., 2006).  These data would support the hypothesis that the increase in release and 
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uptake seen in brain slices is not due to increased nerve innervation in this region but an 
alteration in terminal dynamics.  Increased dopamine release could be the result of 
improved vesicle packaging, upregulated dopamine synthesis or altered Ca2+ dynamics, all 
ATP-dependent neuronal processes (Burgoyne and Morgan, 2003; Chen et al., 2003; 
Stokes and Green, 2003).  The relationship between UCP2 and DAT function is less clear 
because the transport of dopamine into the presynaptic terminal is a passive process 
(Justice et al., 1988; Torres, 2006).  However, dopamine is co-transported with Na+ along its 
concentrations gradient (Kandel, 2008).  The Na+ gradient is established in part by an ATP 
dependent Na+/K+ pump (Hodgkin and Huxley, 1952).  The efficiency of this pump could 
have an effect on the efficiency of dopamine uptake through DAT, altering the Vmax 
measurement.  As stated previously, the slice results represent a departure from the current 
hypothesis positively relating UCP2 to dopamine cell viability.  One report showed 
decreased dopamine turnover in the caudate putamen of UCP2 KO animals as measured 
by the DA/DOPAC ratio (Andrews et al., 2006).  The electrochemical measurements (a 
direct measurement of actual dopamine concentrations) described here would argue against 
a decrease in dopamine release.  It is quite possible that the improved energetic state of the 
presynaptic terminal increased the efficiency of the monoamine oxidase enzyme responsible 
for breaking down dopamine into DOPAC.  The DA/DOPAC ratio would still be altered in 
UCP2 KO animals but would no longer represent a decrease in dopamine activity.   
 The role of UCP2 in the modulation of dopamine release remains controversial.  
Divergent theories as to the exact function of UCP2 in brain mitochondria prevent the 
development of a focused hypothesis.  It is unlikely that such a large disruption would have 
a singular effect on neurotransmitter dynamics.  Therefore, a mixture of effects in UCP2 KO 
animals is likely.  Future work has begun to focus on the selective removal of UCP2 in 
dopamine neurons only as well as a more complete characterization of how protein levels 
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are altered in the striatum of these animals.  Much more work is necessary before a solid 
mechanism of UCP2 action can be devised. 
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Chapter 6 
Content Analysis by High Performance Liquid Chromatography 
 
Introduction 
 Mikhail Tsvet is often credited with performing the first chromatographic separation in 
1901 when he resolved plant components on calcium carbonate using ethanol/ether mobile 
phases (Hadden, 1971).  It’s been a little over 100 years since that ‘first’ separation and 
liquid chromatography has become one of the more prolific analytical tools for the modern 
day chemist.  This chapter will focus solely on the use of reversed phase high performance 
liquid chromatography (RP-HPLC) for the separation and quantification of biogenic amines 
in complex samples. 
 Liquid chromatography separates analytes based on their polarity.  In RP-HPLC, the 
stationary phase is non-polar while the mobile phase is of varying polarity.  The stationary 
phase is bonded to a silica support, usually a spherical particle.  The most traditional 
stationary phases for reversed phase chromatography are straight chain n-alkanes (C5-
C30), although more elegant stationary phases (ie. bonded phenyl) are made for a variety of 
applications.  Analytes partition between the bonded stationary phase and the flowing 
mobile phase; the amount of time spent by the analyte in either phase will dictate the time it 
takes to elute from the column.  The time taken by an analyte to elute from the column is 
called the retention time (tR), a species dependent property that can be manipulated by 
changing the separation parameters.  On a reversed phase column, non-polar analytes 
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spend more time in the stationary phase than polar analytes thus eluting from the column at 
a later time.  The stationary phase is the primary site of separation; therefore, reversed 
phase chromatography is best suited for the separation of non-polar compounds. 
 Mobile phase compositions are critical for the efficient separation of analytes via 
liquid chromatography.  The relative polarity between the mobile phase and the stationary 
phase affects the partitioning coefficient (a term that expresses a molecule’s affinity for 
either phase) for a given analyte.  As the mobile phase increases in polarity, the analyte will 
spend more time in the stationary phase and elute later.  As the polarity of the two phases 
become similar, retention times will decrease because the analyte will spend more time in 
the mobile phase.  The power of reversed phase separations for biological applications is in 
the ability to use aqueous based solvents as the mobile phase.  Water based mobile phases 
make separations simpler, cleaner, and more easily connected to tandem separation 
methods like capillary electrophoresis or electrospray ionization for mass spectrometry 
(Zhang et al., 2008; Zhao and Suo, 2008).  Typically, a small amount of organic solvent (10-
20 %) is added to the mobile phase to decrease analyte retention by increasing the organic 
character of the aqueous mobile phase.  For an isocratic elution, the composition of the 
mobile phase does not change during the analysis time while in a gradient elution the mobile 
phase composition is altered over the course of the run.  Isocratic elutions suffer from poor 
resolution at low retention times and peak broadening at longer retention times.  Gradient 
elutions circumvent these problems by increasing the separation of less retained analytes 
while forcing heavily retained analytes off of the column, preserving their shape and 
decreasing analysis time. 
 Electrochemical detectors (ECDs) are used to monitor analytes by measuring the 
current that arises from their oxidation or reduction on an electrode surface placed at the 
column outlet.  ECDs used for the analysis of brain lysates have an advantage over other 
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detector technologies such as UV-Vis or mass spectrometry because they are insensitive to 
the brain matrix, consisting mostly of small peptides and lipids (Ramstrom et al., 2009).  The 
lack of sensitivity for these matrix components provides simpler chromatograms that are 
more easily interpreted.  This simplicity has made RP-HPLC with ECD desirable for 
researchers looking into the distribution of biogenic amines in response to environmental 
stimuli or pharmacological manipulation (Vriend and Dreger, 2006; Filipov et al., 2007).   
 This chapter focuses on the use of RP-HPLC to support electrochemical 
measurements of biogenic amines in the brain.  RP-HPLC with ECD was used to quantify 
total content of dopamine and 5-HT in transgenic animals that have disruptions in stimulated 
neurotransmitter release measured by electrochemistry.  Chromatography was also 
necessary to determine the relative amounts of two biogenic amines, dopamine and 
norepinephrine (NE), in the ventral bed nucleus of stria terminalis (vBNST) in support of 
mixed electrochemical signals.  RP-HPLC with ECD was used to measure biogenic amine 
total content in non-neuronal tissue samples.  The presence of dopamine, NE, and 
epinephrine (E) in the mouse adrenal gland was confirmed by RP-HPLC with ECD.  Finally, 
chromatography was used to help quantify the component of electroosmotic flow (EOF) in 
the barrel of an iontophoresis probe in an attempt to better quantify iontophoretic ejections 
(Herr et al., 2008). 
Materials and Methods 
 A full description of all techniques used in this chapter can be found in Chapter 2. 
Results 
 Five compounds most commonly found in the parts of the brain related to 
dopaminergic transmission were separated using isocratic elution reversed phase RP-
HPLC, which is shown in Figure 6.1.  The following compounds were injected as standards 
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at a concentration of 1 μM in 0.1 N perchloric acid: NE, E, dopamine, l-dopa, and DOPAC.  
The mobile phase for this elution consisted of citric acid, hexyl sodium sulfate, EDTA, and 5 
% methanol.  All of the compounds were baseline resolved from one another and from the 
internal standard HQ, used for quantification.  The most closely eluting peaks are E and NE 
which are also the earliest eluting peaks with a tR only 2.5 minutes after the dead time 
marker (Figure 6.1).  Less separation between these analytes is not surprising as they are 
virtually un-retained on the analytical column and differ in structure only by a methyl group 
on the primary amine.  DOPAC is the most retained peak eluting at a tR of 22 minutes, ~3 
minutes after dopamine.  The chromatogram in Figure 6.1 clearly demonstrates that even 
with an isocratic elution most analytes of interest can be separated by RP-HPLC. 
Total Content Analysis of Transgenic Animals 
 The analysis of tissue homogenate by RP-HPLC was used to determine total 
neurotransmitter content in transgenic mouse models.  Homogenate taken from the caudate 
putamen of a WT animal indicates the presence of only dopamine (Figure 6.2).  There is no 
indication that the dopamine precursors or metabolites are present in this sample.  An 
additional peak, ascorbate, not present in the standard injection (Figure 6.1) is present in the 
tissue homogenate.  Ascorbate is not retained on an RP-HPLC column; therefore, it elutes 
on top of the perchloric acid solvent front that marks the column dead time (Figure 6.2, peak 
2).  The presence of an overwhelming ascorbate peak is characteristic of all tissue 
containing samples and serves as a reliable injection quality marker.  The chromatograms 
from the caudate putamen of transgenic mice are qualitatively similar to that shown for WT 
animals. 
 The total content of four different transgenic mice was measured (n ≥ 4, all 
genotypes) with RP-HPLC (Table 6.1).  Dopamine measurements were made in the caudate  
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Figure 6.1  Isocratic separation of biogenic amines using RP-HPLC.  Separations were 
performed on a Waters® Symmetry column (4.6 mm X 250 mm, C18  5 µm bonded particles) 
in a citric acid mobile phase ( 0.1 M citric acid, 1 mM hexyl sodium sulfate, and 0.1 mM 
EDTA, pH 3, 5 % methanol).  Electroactive species were detected using a thin-layer radial 
flow cell held at a constant +700 mV.  Peak identifications: 1- dead time marker (perchloric 
acid), 2- NE, 3- E, 4- l-dopa, 5- hydroquinone (HQ) (Std.), 6- dopamine, and 7- DOPAC. 
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Figure 6.2  Total content analysis of caudate putamen tissue samples taken from mouse 
brain slices.  HQ is in the extraction buffer at 1 M to allow for quantification of identified 
analytes in the tissue sample.  Peak identifications: 1- solvent front, 2- ascorbic acid, 3- HQ, 
4- dopamine.  In caudate putamen tissue, dopamine is the only detectable catecholamine. 
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putamen and the ventral tegmental area (VTA).  5-HT measurements were made in 
substantia nigra pars reticulate (SNr) and the VTA.  These animals show a 3-fold range of 
dopamine content values in the caudate, but a very similar amount of 5-HT in the VTA and 
SNr.  Mice expressing enhanced green fluorescent protein (eGFP) do not exhibit a change 
in dopamine total content in the caudate putamen nor the VTA when compared to WT mice 
(Table 6.1).  This trend is also seen in transgenic mice lacking the presynaptic protein 
synapsin (synapsin TKO) which show no change in striatal dopamine.  Mice insensitive to 
leptin exhibit a significant (p < 0.05) decrease in their striatal dopamine content compared to 
WT mice.  However, mice lacking uncoupling protein 2 (UCP2) did not show a significant (p 
> 0.05) change in striatal dopamine content compared to WT mice (Table 6.1). 
Total Content Changes in Brain Regions of the Rat 
 Measurements by RP-HPLC were used to demonstrate a gradient in 
neurotransmitter content in the vBNST of the rat brain.  Electrochemical measurements in 
this area indicate a signal comprised of both dopamine and NE.  Brain tissue homogenate 
taken from this area was analyzed by RP-HPLC to determine the relative amounts of 
dopamine and NE in parts of this brain region (Figure 6.3).  Total content analysis indicated 
the presence of dopamine and NE; 5-HT was not detected in these samples.  The 
anteromedial portion of the vBNST had a roughly 1:2 ratio of dopamine:NE while the 
medioposterior vBSNT had a 1:10 dopamine:NE ratio (Figure 6.3).  These ratios are quite 
similar to those previously reported (Kilts and Anderson, 1986).  The ratiometric change 
between the two regions is due to a decrease in dopamine content concomitant with a three-
fold increase in NE content. 
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Table 6.1  Total content of dopamine and 5-HT in transgenic mouse models.  The amount of 
dopamine and 5-HT per gram of tissue is shown for eGFP mice, synapsin transgenic mice, 
leptin transgenic mice, and UCP2 transgenic mice.  Dopamine was identified as the sole 
biogenic amine in the caudate putamen of all mouse types.  In the substantia nigra, 5-HT 
was the only detectable biogenic amine.  The ventral tegmental area (VTA) contained both 
dopamine and 5-HT.  (*, p < 0.05, Student’s t-test, WT vs. Leptin KO)   
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Figure 6.3  The biogenic amine profile of the ventral bed nucleus of the stria terminalis 
(vBNST) as determined by RP-HPLC.  Tissue samples (shown as the colored sections) 
were micro-dissected by hand from brain slices and analyzed for the anteromedial and 
medioposterior sections of the vBNST.  Slice schematics and sterotaxic coordinates for both 
regions are shown in the top panel, both colored regions were removed and homogenized.  
The total content distribution of dopamine, norephinephrine, and 5-HT are shown in the 
bottom panel.  The ratio of norepinephrine to dopamine increases as you move posterior 
within the vBNST.   
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Biogenic Amine Distribution in Murine Adrenal Glands 
 The ability to measure biogenic amine concentrations by RP-HPLC is not limited to 
brain tissue homogenates.  The technique used for brain homogenate can be extended to 
tissues taken from the peripheral nervous system.  Of particular interest is the biogenic 
amine profile of the adrenal gland which is responsible for the release of E and NE into the 
blood stream upon induction of a stress response.  The adrenal gland consists of chromaffin 
clusters (containing about 20 cells each) oriented adjacent to the vascular system (Barbara 
et al., 1998) (Kajiwara et al., 1997) (Figure 6.4A).  The individual chromaffin cells are 
capable of releasing either E or NE, which diffuses to the vasculature and is carried by the 
blood stream to peripheral targets.  Whole adrenal glands were homogenized in 500 µL of 
0.1 N perchloric acid.  The only biogenic amines detected in these samples were NE, E, and 
dopamine.  There were large amounts of E and NE (180 and 350 µg/g respectively) and a 
relatively small of dopamine (< 10 µg/g); furthermore, the E:NE ratio was found to be 2 
(Figure 6.4B).  These data are consistent with that found in the literature for the content of 
adrenal glands analyzed by RP-HPLC (Ally et al., 1986). 
Analyzing Iontophoretic Ejections 
 RP-HPLC was used to help quantify the contribution of EOF to the ejection rate of 
analytes by iontophoresis (Herr et al., 2008).  An electron micrograph of an iontophoretic 
electrode with four open capillaries is shown in Figure 6.5A.  A bolus of analyte is ejected 
through one of these capillaries by the application of a driving force, in this case, current 
(Figure 6.5A).  To determine the relative rates of ejection for neutral and charged molecules, 
ten minute ejections of dopamine, HQ, and acetamidophenol (AP) were done into 500 µL of 
0.1 N perchloric acid using a modified recording chamber shown in Figure 6.5B.  Figure 
6.6A shows the successful isocratic separation and detection of ejected dopamine and AP  
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Figure 6.4  Adrenal glands contain biogenic amines in high concentrations as reported by 
RP-HPLC total content analysis. A)  A light micrograph of an adrenal slice shows chromaffin 
cell clusters arranged around the venous blood supply.  Photo courtesy of Jelena Petrovic.  
B)  Whole glands (n = 4) where homogenized in 500 µL of 0.1 N perchloric acid, and their 
content analyzed by RP-HPLC.  There is roughly a 2-fold higher content of E in adrenal 
slices compared to NE; DA content is very low in comparison.  
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Figure 6.5  Iontophoretic ejections of electroactive analytes for RP-HPLC analysis.  A)  An 
electron micrograph showing an iontophoretic electrode with the carbon fiber sensor 
oriented on the top of four open capillaries.  The open capillaries can be used to eject 
chemicals into the area surrounding the electrode by applying a current of the same polarity 
as the species being ejected.  B)  The apparatus used to collect the total amount of ejected 
material.  An ejection was done into 500 µL of perchloric acid with connections made for the 
reference electrode, working electrode, iontophoretic current applied, and the current return.   
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Figure 6.6  Analytes ejected from the barrel of an electrophoretic probe quantified using RP-
HPLC analysis.  A) Isocratic separation of iontophoretically ejected dopamine (DA) and 
acetamidophenol (AP) from the internal standard HQ.  Separations were performed as 
described in Figure 1 with the exception that 10 % methanol was used.  Peak identifications: 
1- solvent front (perchloric acid), 2- HQ (internal standard), 3- DA, 4- AP.  B) The amount of 
ejected compound was used to quantify the rate of ejection for HQ, DA, and AP (n, the 
number of barrels tested).  HQ and AP are both neutral compounds and are therefore 
ejected at the same rate.  DA is positively charged leading to a faster ejection rate than the 
neutral AP (***, p < 0.001, t-test).   
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(the EOF marker for these experiments).  Figure 6.6B shows the rate of total ejection 
relative to EOF for a charged analyte, dopamine, and an uncharged analyte, HQ.  The 
HQ:AP ratio was 1.04 while the DA:AP ratio was 1.75 (Figure 6.6B, n ≥ 3 electrodes) 
indicating that HQ is ejected at the same rate as EOF while dopamine is ejected at a faster 
rate than EOF.  These conclusions support those obtained using FSCV that show the rate of 
ejection for charged molecules is higher than that of uncharged molecules (Herr et al., 
2008).   
Discussion 
 Independent validation of a result by multiple analytical techniques is critical in 
neuroscience where divergent theories cannot be supported or refuted with a single 
technique.  For example, one of the key requirements for complete validation of new in vivo 
biosensors is validation via established analytical techniques (Phillips and Wightman, 2003).  
A similar set of standards should be adopted when evaluating newly formed transgenic 
animals or novel brain regions.  RP-HPLC is a technique that can be used to help validate 
conclusions drawn from electrochemical evidence because it provides a different viewpoint 
on the state of biogenic amines. 
Isocratic Elutions of Biogenic Amines 
 RP-HPLC using isocratic elution with a single pH buffer is adequate for the 
separation of biogenic amines.  Biogenic amines are baseline resolved when run on a 
reversed phase C18 column using citric acid mobile phase (pH 3.5) containing 5 % 
methanol as an organic modifier (Figure 6.1).  Although adequate for these purposes, there 
are limitations to a separation of biological samples by isocratic elution.  Closer examination 
reveals two clusters of retained compounds, the first of which occurs prior to 10 minutes.  
Within the first cluster are peaks 2 and 3 (NE and E) which are not completely resolved from 
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one another.  These less retained analytes would benefit from a lower methanol 
concentration which would increase their overall tR and resolution.  However, a second pair 
of peaks (dopamine and DOPAC) are late eluting compounds (> 20 min.) indicating that they 
are highly retained on the column.  As is typical in an isocratic elution, these late eluting 
peaks have become short and broad; an undesirable quality for chromatographic peaks 
(Neue, 1997).  Lowering the methanol concentration would only exacerbate these problems 
potentially eliminating these peaks altogether.  This classical problem is most easily 
addressed using a gradient elution.  A linear increase in the concentration of organic 
modifier could be used to maintain positive separation for peaks 2-5 while improving the 
shapes of peaks 6 and 7 by forcing them off of the column more quickly.  Gradient elutions 
have previously been coupled with electrochemical detectors for the determination of brain 
analytes (Smolders et al., 1995; Kilts et al., 1996; Yun et al., 1998).  The investigation of 
gradient methodologies in this work was hampered by instrumentation but should remain the 
top priority for future method development. 
 The isolation of biogenic amines from tissue homogenates can be used to quantify 
their concentration.  Tissue samples taken from the caudate putamen of the mouse indicate 
the presence of two electroactive neurotransmitters, ascorbate and dopamine (Figure 6.2).  
An overwhelming large ascorbate peak is expected when analyzing biological samples 
because ascorbic acid is found in the extracellular space at a concentration of 400 µM 
(Brahma et al., 2000).  The dopamine peak arises from dopamine residing in vesicles of 
dopamine neurons that synapse with medium spiny neurons in the dorsolateral striatum 
(Jones et al., 1995).  Ascorbate is not retained on a reversed phase column so it elutes 
within the solvent front.  The retention times of HQ and dopamine in Figure 6.2 differ from 
those shown in Figure 6.1 because a higher methanol concentration (10 % instead of 5 %) 
was used to improve peak shape.  Experiments done at lower methanol concentrations 
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were used to confirm the absence of early eluting compounds (NE) that would have become 
unretained at a methanol concentration of 10 %.  Other areas of the striatum such as the 
nucleus accumbens have a small amount of NE present in addition to the dopamine (Park et 
al., in preparation).  However, no detectable NE was found in the mouse caudate by RP-
HPLC. 
Neurotransmitter Contents in Genetically Altered Mice 
 Transgenic mouse models with altered neurotransmitter release have been analyzed 
by RP-HPLC to help determine the origin source of altered neurotransmitter dynamics in 
these animals.  It is beyond the scope of this chapter to discuss all of the electrochemical 
release data associated with these genotypes; however, additional information is provided in 
other chapters.  Here we will focus on the power of RP-HPLC to confirm or refute the 
assumption that the dopamine stores in these animals remain unchanged. 
 Mice expressing eGFP are used to positively identify neurons expressing tyrosine 
hydroxylase, the rate limiting enzyme in dopamine synthesis (Kessler et al., 2003).  Positive 
identification of dopamine neurons is beneficial to researchers studying isolated neurons, 
diffuse terminal fields, or brain regions where anatomical landmarks are not present (Miller 
et al., in preparation).  Before these mice could be used regularly, they were evaluated for 
any possible changes in dopaminergic transmission by Dr. Charles Miller.  The evaluation of 
neurotransmitter content by RP-HPLC was one component of this evaluation.  Total content 
measurements were taken in caudate putamen, a dopamine terminal field and in the VTA, 
the location of dopamine cell bodies.  Dopamine was the only biogenic amine detected in 
the striatal homogenate, while both dopamine and 5-HT were detected in the VTA (Table 
6.1).  The caudate putamen results are not surprising for reasons discussed earlier, and 
neither are those from the VTA.  Dopamine neurons in this region are capable of 
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somatodentric release; therefore, a certain level of dopamine stores must be maintained 
(John et al., 2006).  In addition, 5-HT neurons from the dorsal raphe nucleus modulate cell 
firing at dopamine neurons in the VTA (Adell and Artigas, 2004).  Regardless of the region 
or the neurotransmitter of interest, there was no observed change in biogenic amine 
concentrations in eGFP positive animals.   
Synapsin TKO animals release larger amounts of dopamine than their WT 
counterparts (Chapter 3).  These mice lack a presynaptic protein, synapsin, which regulates 
the availability of vesicles for release (Greengard et al., 1993; Lonart and Simsek-Duran, 
2006).  Our work has demonstrated that this disruption leads to enhanced stimulated 
release in dopamine neurons only (Kile et al., submitted).  The question follows: Does this 
enhancement of release relate back to an increase in overall dopamine availability?  
Dopamine total content measurements taken from the caudate putamen of the mouse brain 
indicate an equivalent amount of dopamine in WT and synapsin TKO animals (Table 6.1).  
This result implies that the changes in stimulated dopamine release in synapsin TKO 
animals are not related to a change in the overall amount of brain dopamine.  Total content 
measurements indicated no 5-HT content difference in the SNr, where no difference in 
electrically stimulated 5-HT release was found electrochemically.  These data taken with 
those already discussed in Chapter 3 strongly indicate that the change in stimulated 
dopamine release in synapsin TKO animals is related to changes in release probabilities or 
presynaptic architecture rather than a change in vesicle size or number.   
Striatal dopamine content is reduced in leptin deficient animals, but unchanged in 
UCP2 deficient animals.  Mice genetically altered to be leptin deficient have phenotypes 
such as obesity, diabetes, and decreased movement (Chapter 5).  Leptin is known to 
modulate striatal dopamine stores at the cell bodies (Roseberry et al., 2007).  Total content 
analysis in the caudate putamen was performed to confirm the hypothesis that mice lacking 
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leptin have less dopamine projections from the substantia nigra to the caudate (Chapter 5).  
The total content was taken on three animal genotypes: wild type animals, animals lacking 
leptin, and animals lacking UCP2.  Leptin insensitivity leads to a significant (p < 0.05) 
decrease in the striatal content of dopamine as determined by RP-HPLC (Table 6.1).  This 
result is consistent with previous work indicating decreased dopaminergic innervation in this 
brain region as measured by DAT binding (South and Huang, 2008).  Interestingly, knocking 
out UCP2 alone does not enhance the amount of dopamine in the striatum even though it 
enhances stimulated dopamine release (Chapter 5).  The RP-HPLC data refutes the 
hypothesis that the changes in stimulated dopamine release seen in these animals is due 
solely to changes in terminal innervation.   
There are three primary sources of error contributing to the content data shown in 
Table 6.1.  The first source of error deals with any inconsistencies in the dissection area 
whether in the slice depth or the ability to efficiently isolate the area of interest prior to 
homogenization.  This variability is unavoidable and can be seen in the relatively large SEM 
vales shown in Table 6.1.  Smaller brain regions (VTA and SNr) have a larger percent SEM 
than the caudate because dissection error in these regions is more likely.  The variability 
sources discussed above do not account for the wide range of reported striatal dopamine 
contents in Table 6.1.  This range is due to differences in the sampling region (mainly the 
anterior-posterior depth of the caudate slice taken).  The RP-HPLC slice used for total 
content analysis was designed to be the same as the slice used for the electrochemical 
measurements.  The electrochemical measurements were done in different striatal locations 
for different experiments due to study specific parameters.  There is a significant anterior to 
posterior gradient of dopamine innervation in the mouse brain affecting the total content 
measurement taken from tissue samples at different depths.  Finally, there is variability 
between transgenic mouse lines due to the simple fact that they are transgenic animals.  For 
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example, the synapsin TKO animals were bred on a mixture of three different mouse 
backgrounds while the eGFP mice were on a pure C57 BL/6 background.  This difference 
alone will impart large amounts of measurement variability.  These error sources are not a 
limitation of the technique; they are a reminder that littermate WT animals must be used 
whenever possible to eliminate as much animal to animal variability as possible.   
Biogenic Amine Profiles by RP-HPLC 
 Total content analysis by RP-HPLC is important for studies in brain regions where 
multiple biogenic amines contribute to the electrochemical signal.  Electrically evoked 
neurotransmitter release in vivo produces a FSCV signal in the vBNST that is composed of 
NE and dopamine (Park et al., accepted).  The cyclic voltammograms of NE and dopamine 
are not sufficiently different to positively identify the signal’s origin (Heien et al., 2003).  In 
addition, the relative amounts of dopamine and NE are differ you move from an 
anteromedial position (bregma + 0.36) to a medioposterior position (bregma + 0.0).  The 
total content profile of NE and dopamine by RP-HPLC in these two regions indicate that 
there is more NE and less dopamine in the medioposterior region leading to a larger 
NE:dopamine ratio (Figure 6.3).  These data are in good agreement with previous RP-HPLC 
studies performed in this brain region (Kilts and Anderson, 1986).  They also support the 
electrochemical and pharmacological evidence that NE composes a greater percentage of 
the current signal in the medioposterior region (Park et al., submitted).  A small number of 
studies have indicated the presence of 5-HT in this brain region; however, any 5-HT present 
in these samples was below our detection limits. 
 As stated in the results section, RP-HPLC can also be used to evaluate biogenic 
amine distributions in peripheral tissues of the neuroendocrine system.  Adrenal glands 
consist of chromaffin cell (the biogenic amine releasing cell) clusters immediately adjacent to 
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a vein wall (Figure 6.4).  The presence of large amounts of NE and E are expected because 
the main function of the adrenal gland is direct infusion of NE and E into the blood stream.  
Whole adrenal glands were analyzed by RP-HPLC to determine the ratio of NE:E and the 
presence of any other electroactive substances (Figure 6.4).  There is twice as much 
epinephrine in mouse adrenal slices as norepinephrine which is consistent with literature 
reports (Ally et al., 1986; Vollmer et al., 1992).  Interestingly, a small amount (relative to the 
E concentration) of dopamine was also found.  The role of dopamine in the adrenal gland 
has not been well established; however, upregulation of tyrosine hydroxylase has been 
demonstrated in response to prolonged stress (Tank et al., 2008). 
Evaluating Iontophoretic Ejections by RP-HPLC 
 Iontophoresis is a drug delivery system that uses an applied current to drive analytes 
(charged or uncharged) through an open capillary tube (Figure 6.5A).  Uncharged particles 
are expelled from the barrel by means of EOF (the movement of bulk ionic solution under an 
applied potential) only.  Positively charged particles are expelled from the barrel because 
they are repelled by the positive current applied to the capillary; they also move along with 
the EOF.  The contribution of EOF to the overall rate of drug application is variable, 
preventing accurate determination of the amount of material ejected.  RP-HPLC was used to 
help quantify the contribution of EOF to the overall ejection rate facilitating more quantifiable 
iontophoretic ejections (Herr et al., 2008).  Iontophoretic ejections were performed into a 
small volume for RP-HPLC analysis of total analyte flux into the surrounding solution (Figure 
6.5B).  For the study shown, AP was used as a marker of EOF.  RP-HPLC successfully 
resolved the three compounds used in this experiment: AP, HQ, and dopamine (Figure 
6.6A).  As expected, there is no difference in the amount of HQ ejected when compared to 
AP (Figure 6.6B).  HQ is an uncharged molecule that should only be ejected from the barrel 
at a rate equal to the EOF.  Dopamine, however, is ejected at a faster rate than AP because 
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it is also experiencing a repulsion event due to the application of a positive current pulse.  
These relationships are in good agreement with those obtained using FSCV (Herr et al., 
2008).  Charged molecules are ejected more quickly than uncharged molecules resulting in 
a locally higher analyte concentration (higher FSCV signal) and an overall higher flux of 
material (larger RP-HPLC peak area) into the surrounding volume. 
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Chapter 7 
Disease State Mouse Models 
 
Introduction 
Obesity alters human physiology in part by limiting the arterial blood supply to the 
heart, decreasing the ability for the pancreas to measure blood sugar levels, and slowing 
digestion.  The effects of obesity are not limited to the periphery; changes have been seen 
in brain structures such as the hypothalamus and cortex.  The relationship between 
increased body weight and neurotransmission is important; food is one of a handful of 
naturally rewarding substances (Stoeckel et al., 2008; Stice et al., 2009).  The physiological 
drive for food intake originates in the hypothalamus where the hormones ghrelin and leptin 
regulate hunger and satiety (Broberger, 2005; Bomberg et al., 2007).  Leptin in particular 
has been shown to modulate dopamine levels in the mesoaccumbens pathway altering the 
rewarding benefits of food intake (Figlewicz and Benoit, 2009).  A complete understanding 
of how brain chemistry is altered during the obese state may provide insight into possible 
anti-obesity treatments. 
 Leptin has long been implicated as the ‘fat’ hormone because it is partly responsible 
for the cessation of food intake.  Free floating leptin binds to hypothalamic receptors 
inducing a feeling of satiety (Figlewicz and Benoit, 2009); furthermore, the action of leptin 
appears to decrease dopamine release from hypothalamic nerve endings (Brunetti et al., 
1999).  Leptin insensitivity or leptin resistance has been implicated as a cause of obesity in 
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Figure 7.1  Mice lacking the hormone leptin are prone to hyperphagia leading to morbid 
obesity.  The mouse shown on the left is a normal C57 strain mouse.  The mouse on the 
right is the same strain of animal lacking leptin and given an unrestricted access to food 
pellets.  The ob/ob animal has a total body mass roughly seven times his WT littermate.  
Both mouse strains are available from Jackson Laboratories.  Photo courtesy of 
http://www.genomenewsnetwork.org.   
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some cases (Myers et al., 2008).  Mice genetically altered to no longer produce leptin (ob/ob 
mice) are a good obesity model because they exhibit phenotypical hyperphagia 
(overeating), a process that requires dopamine (Szczypka et al., 2000).  The hyperphagia in 
ob/ob mice results in a profoundly obese animal susceptible to diabetes (Figure 7.1).  The 
ob/ob transgenic animal has previously been used to evaluate the relationship between 
leptin, obesity and dopamine release.  Leptin was shown to act in the midbrain as a positive 
modulator of dopamine release in these animals (Fulton et al., 2006; Roseberry et al., 
2007), much different from its negative modulation in the hypothalamus (Brunetti et al., 
1999).  However, studies done in normal mice indicate that the simple act of high fat feeding 
is able to alter D2, D4, and DAT levels in the mouse striatum and TH levels in the ventral 
tegmental area (VTA) (South and Huang, 2008; Li et al., 2009). 
 Fragile X syndrome (FXS) is the most commonly inherited form of cognitive 
deficiency in humans.  FXS is a triple repeat disorder in which the proliferation of an CGG 
repeat within the promoter region of Fmr1 leads to gene inactivation (Bassell and Warren, 
2008).  The Fmr1 gene codes for fragile X mental retardation protein (FMRP), believed to be 
necessary for the proper transcription of many other mRNAs in the cell (Brown et al., 2001; 
Darnell et al., 2001).  In particular, FMRP appears to regulate mRNAs expressed upon 
activation of metabotropic glutamate receptors regulating synaptic plasticity (Bureau et al., 
2008).  The Dutch Consortium (1994) generated a FXS disease state model by directly 
knocking out the Fmr1 gene.  A large amount of research has been done on these mouse 
models aimed primarily at understanding how synaptic plasticity is altered in FXS (Bear et 
al., 2008).  There has been little evidence suggesting dopamine as a component of FXS 
despite phenotypic hyperactivity disorders in some FXS patients.  However, FMRP was 
recently shown to be required for dopamine modulation of synaptic plasticity in the prefrontal 
cortex (PFC) through action of D1 receptors (Wang et al., 2008).  Additionally, amphetamine 
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was able to improve object recognition performance in Fmr1 KO mice coincident with a 
preferential increase in PFC dopamine levels over WT animals (Ventura et al., 2004). 
 This chapter focuses on preliminary release experiments performed in obesity and 
mental retardation disease state models.  The ob/ob disease state mouse model for obesity 
results in decreased dopamine release and uptake as measured in striatal brain slices.  This 
is consistent with previous work demonstrating decreased dopaminergic acitivity due to 
leptin deficiency as well as hyperphagia.  The Fragile X syndrome disease state model 
showed no alterations in neurotransmitter release from the caudate putamen, vBNST, or 
SNr consistent with the theory that Fragile X syndrome results from disruption of 
postsynaptic signaling.   
Materials and Methods 
 A full description of techniques used in this chapter can be found in Chapter 2.  
Disclaimer 
 Part of this chapter contains data taken in collaboration with the lab of Dr. Brad 
Lowell at Beth Israel Deaconess Hospital in Boston, Massachusetts.  My direct contact 
person at this lab provided me with the genetic identities of the ob/ob mice and WT control 
mice used in this study.  This contact person was recently removed from his/her position due 
to academic misconduct in regards to the study relating UCP2 upregulation to 
neurotransmission in obesity.  The genetic identities of the animals provided to me have in 
one form or another been confirmed by the Lowell lab as being correct; therefore, I stand 
behind the results shown here and the conclusions drawn from them. 
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Results 
Stimulated Dopamine and 5-HT Release in ob/ob Animals 
 The effect of leptin deficiency on stimulated biogenic amine release was evaluated 
using brain slices.  Dopamine release was evoked with a single pulse electrical stimulation 
and detected with FSCV in striatal brain slices containing the caudate putamen from WT 
mice and ob/ob mice.  Data pooled from multiple animals (4 sites within each animal) of 
each genotype showed that ob/ob animals release significantly less (p < 0.001, one-way 
anova, n = 9 both genotypes) dopamine than WT animals (Figure 7.2A).  This was not the 
case for 5-HT release evoked from the SNr of WT and ob/ob animals using a 20 pulse 100 
Hz stimulation (Figure 7.2B).  Under these conditions, there was no significant difference in 
the amount of 5-HT released between WT and ob/ob animals (p > 0.05, one-way anova, n = 
9 both genotypes). 
 Obese animals have decreased levels of DAT expression in the striatum (South and 
Huang, 2008).  For this reason, the average Vmax of dopamine uptake was measured in the 
caudate putamen of WT and ob/ob animals using FSCV with temporal deconvolution and 
simplex non-linear regression (Chapter 2).  The Vmax of dopamine uptake was significantly 
lower (p < 0.001) in ob/ob animals when compared to WT animals (Figure 7.3, one way 
anova, n = 9 both gentoypes). 
Biogenic Amine Release in Fragile X Mutant Mice 
 Possible presynaptic alterations in Fmr1 KO mice were evaluated using brain slices 
containing the caudate putamen, vBNST, or SNr (Figure 7.4).  Electrically stimulated 
dopamine release (single pulse) monitored by FSCV was unchanged in Fmr1 KO mice when 
compared to WT mice (p > 0.05, n = 6 both genotypes).  Additionally, NE release in the 
vBNST by a 60 pulse 60 Hz stimulation was not different (p > 0.05, n = 6 both genotypes)  
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Figure 7.2  Leptin deficiency affects striatal dopamine release but not stimulated 5-HT 
release in the substantia nigra.  A) Stimulated dopamine release in the caudate putamen of 
ob/ob mice is significantly reduced (n = 9, *** p < 0.001, one-way anova).  B) There is no 
significant difference in stimulated 5-HT release between WT animals or ob/ob animals ( p > 
0.05, n = 9). 
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Figure 7.3  The maximal rate of dopamine clearance is changed in ob/ob mice.  Temporal 
deconvolution and simplex modeling of dopamine traces were used to assign a Vmax  for 
dopamine uptake.  As seen with dopamine release, the Vmax of dopamine uptake is 
significantly reduced in ob/ob mice compared to WT animals (***, p < 0.001, one-way anova, 
n = 5 both genotypes).   
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Figure 7.4  Stimulated neurotransmitter release in three regions of the adult mouse brain.  
Brain slices containing the caudate putamen, vBNST, or SNr were taken from WT mice and 
Fmr1 KO mice.  Dopamine release evoked by a single pulse electrical stimulation was 
unchanged in Fmr1 KO mice compared to WT mice (p > 0.05, n = 6 both genotypes).  The 
same can be said for 5-HT release evoked by a 20 pulse 100 Hz stimulation in the SNr and 
NE release evoked by a 60 pulse 60 Hz stimulation in the vBNST (p > 0.05, n = 6 both 
genotypes). 
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between Fmr1 KO and WT control animals.  This trend was repeated in the SNr where a 20 
pulse 100 Hz stimulation evoked the same amount of 5-HT release in both animals (p > 
0.05, n = 6 both gentoypes). 
Discussion 
Leptin Removal and Neurotransmitter Release 
 The removal of leptin from a normal C57 inbred mouse strain results in an obese and 
hyperphagic animal.  The obese body state in these animals leads to a host of central and 
peripheral nervous system abnormalities.  In addition to insulin resistance, these animals 
have altered cardiac function, decreased supportive tissue function, and decreased physical 
activity (Lindstrom, 2007).  Many of the peripheral effects of leptin deficiency are 
background strain dependent (they change depending on which mouse line the ob/ob 
mutation was generated) (Lindstrom, 2007); however, all animal types have decreased 
physical movement.  Dopamine regulates movement by acting on medium spiny neurons in 
the striatum; therefore, dopamine release in these animals was evaluated using brain slices.  
Figure 7.2A clearly shows that dopamine release in the striatum of ob/ob mice is significantly 
reduced compared to their WT littermates, a result in direct contrast to stimulated release of 
5-HT (Figure 7.2B) which is leptin independent.  Taken together, these data demonstrate a 
dopamine specific alteration in ob/ob mice.  Decreased dopamine release in ob/ob mice is 
not a novel finding, both somatodendritic and terminal dopamine release are disrupted in 
these animals (Fulton et al., 2006; Roseberry et al., 2007).  In addition, leptin receptors have 
been found on dopamine midbrain neurons (Figlewicz and Benoit, 2009) and are protective 
against 6-hydroxydopamine lesion formation (Weng et al., 2007).  These studies provide 
compelling evidence that the altered dopamine release in ob/ob animals is the result of 
decreased leptin action on midbrain neurons.  However, the hyperphagia/obesity 
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phenotypes demonstrated by ob/ob animals have been shown to alter DAT and D2 levels in 
the striatum and TH levels in the VTA of WT animals (South and Huang, 2008; Li et al., 
2009), alterations consistent with our Vmax (Figure 7.3) and total dopamine content 
measurements (Chapter 6).  These studies support the data shown in Figures 7.2 and 7.3 
but prevent the establishment of a direct link between leptin deficiency and dopamine 
release.  Future work probing dopamine release in diet restricted ob/ob animals and high fat 
fed WT animals may provide clues as to the true cause of dopamine disruption in these 
animals.   
Fragile X Syndrome and Neurotransmitter Release 
 FXS syndrome results from the silencing of the Fmr1 gene which encodes for FMRP, 
a protein most closely linked to glutamate receptors.  Fmr1 KO mice are genetically altered 
to no longer produce FMRP serving as a reliable disease state model for the study of FXS.  
For the first time, FSCV has been used to directly monitor the release of neurotransmitters in 
brain slices from these animals.  Stimulated release of dopamine in the caudate putamen, 
NE in the vBNST, and 5-HT in the substantia nigra are unaffected by the removal of FMRP 
(Figure 7.4).  These findings are not terribly surprising as most FXS patients do not 
demonstrate phenotypes typical of disrupted biogenic amine transmission.  One study in the 
PFC of Fmr1 KO mice did show preferential altered dopamine transmission related to novel 
object recognition (Ventura et al., 2004); however, the data shown in Figure 7.4 would 
indicate that this dopamine effect is limited to the PFC. 
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Chapter 8 
Experimental Parameters and Dopamine Release 
 
Introduction 
It is critical for an experimenter to understand how his/her parameters may affect the 
analytical signal.  In many cases simply performing a measurement will cause a permanent 
and undesirable change in the experimental parameters.  For example, a small dose of 
amphetamine (AMPH) will cause an increase in motor activation; however, too much AMPH 
will decrease motor activation by inducing stereotypy (White et al., 1998).  The stereotypy 
could lead experimenters to underestimate the motor enhancement due to AMPH.  This 
chapter focuses on the aspects of experimentation that may have residual effects on the 
recorded dopamine signal in brain slices.  First, the waveform application frequency is 
discussed as it is important for accurate modeling of dopamine uptake parameters.  Second, 
the effects on dopamine release by drugs used during an experiment such as iontophoretic 
ejection markers or anesthetics will be described.  Finally, a more robust method for the 
measurement of dopamine reverse transport in brain slices will be described.   
Materials and Methods 
 All of experimental procedures used here are explained in complete detail in Chapter 
2.  The use of analog background subtraction for catecholamine measurements over long 
time periods has been explained in detail previously (Hermans et al., 2008).  Principal 
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component regression (PCR) has been used previously to differentiate between signals 
obtained for dopamine with those obtained for pH (Heien et al., 2004).   
Results 
Dopamine Sensitivity and Application Frequency 
 The response of a carbon fiber microelectrode to a 2 µM bolus of dopamine changes 
as a function of the waveform application frequency.  The same electrode has a larger 
current response to dopamine when the waveform is applied at 10 Hz vs. 60 Hz (Figure 
8.1A).  On average, the increase in current response for electrodes cycled at 10 Hz is 70 % 
greater than the current response at 60 Hz (n = 5 electrodes).  There is a two-fold difference 
in the 10-90 % rise time for the two application frequencies being 200 ms at 60 Hz and 400 
ms at 10 Hz (Figure 8.1A). 
Temporal Response of FSCV 
 The signal for dopamine detected with FSCV arises primarily from dopamine that has 
adsorbed to the electrode (Bath et al., 2000).  Because the adsorption occurs in the time 
between voltammetric scans, both the response time and the amplitude of the measured 
current depend on the repetition rate.  To examine how this affects the measurement of 
dopamine dynamics in brain slices, release and uptake evoked by a single stimulation pulse 
were compared when measured with the triangular waveform applied at either 10 Hz or 60 
Hz.  In both cases, the concentration of dopamine increased at the first measurement point 
after the stimulation pulse, its concentration reached a maximum a few points later, and then 
the dopamine concentration returned to prestimulus values (Figure 8.1B).  When the current 
was converted to concentration, the maximal concentrations observed with both repetition 
rates were quite similar.  However, with the 10 Hz repetition rate the maximal response 
occurred 200 ms after the stimulus pulse, whereas it occurred 67 ms after the stimulus with  
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Figure 8.1  The repetition rate of an FSCV electrode changes its sensitivity and temporal 
response to dopamine concentrations.  A) The sensitivity of a carbon fiber microelectrode to 
a 2 µM bolus of dopamine is 70 % higher when the electrode is cycled at 10 Hz instead of 
60 Hz.  B) Stimulated dopamine release in striatal brain slices has a different time course 
when sampled at 10 Hz or 60 Hz.  The peak dopamine concentration occurs at a later time 
(200 ms instead of 50 ms) when the waveform application frequency is reduced from 60 Hz 
to 10 Hz.  The increased temporal delay at 10 Hz leads to an underestimation by 22 % in 
the Vmax value determined by simplex modeling. 
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the 60 Hz repetition frequency.  Since release and uptake occur at the same rate 
irrespective of measurement procedure, this result clearly indicates that the response time of 
the electrode distorts the measurement of uptake.  Further evidence of this is seen in the 
slower rate at which the current returns to baseline with the lower repetition frequency 
(Figure 8.1B).  The uptake portion of both traces was fit to the Michaelis-Menten equation.  
The data collected at 10 Hz had a Vmax value for uptake that was 78 % of the value obtained 
with the data collected at 60 Hz.  The lower value of the Vmax obtained with the 10 Hz 
sampling frequency was obtained even though the increased delay to reach the maximum 
was accounted for by deconvolution (Venton et al., 2002). 
Similar experiments were conducted in the presence of 10 µM cocaine.  The time 
delay is greater under these conditions but increases more with 10 Hz sampling.  
Furthermore, the recorded dopamine concentration is 13% greater when sampling at 10 Hz 
than found with 60 Hz sampling (Figure 8.2A).  Additionally, the disappearance of dopamine 
was qualitatively slower at each concentration of cocaine tested (1 to 20 µM) with sampling 
at 10 Hz.  However, the simplex regression procedure yielded similar values of the apparent 
Km value ((Km)app) for data acquired at both frequencies when the difference in the electrode 
time response was accounted for by deconvolution.  The Ki value at 10 Hz (0.30 μM) was 
the same as that found with a 60 Hz (0.32 μM) repetition rate, both values are similar to that 
previously reported using FSCV with 60 Hz collection (Johnson et al., 2006) (Figure 8.2B). 
Temporal Response of FSCV Compared to Amperometry 
 Although 60 Hz collection frequencies were found to better model dopamine uptake 
in striatal brain slices, there is still concern that the adsorptive delay associated with these 
FSCV measurements would distort the observed time course of uptake, impeding accurate 
assessment of uptake rate constants.  Therefore, uptake rates measured with FSCV  
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Figure 8.2  Differences in the shape of stimulated dopamine release at 60 Hz vs. 10 Hz 
remain even when the uptake rate is slowed by competitive inhibition.  A) Stimulated 
dopamine release in brain slices in the presence of 10 µM cocaine.  B) The decreased rate 
of uptake in the presence of cocaine alleviates the insensitivity to uptake at a 10 Hz 
application frequency when compared to a 60 Hz application frequency.  The Ki values for 
cocaine obtained using a 10 Hz application frequency and a 60 Hz application frequency are 
the same being 0.30 µM and 0.32 µM respectively.   
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collected at 60 Hz were compared with those collected using constant potential 
amperometry.  In the latter technique, dopamine is immediately and continuously oxidized 
as it reaches the electrode surface so adsorption times are not a parameter that affects the 
measurement (Venton et al., 2002).  In this brain slice recording location, the delay time to 
reach a maximum value was 40 ms with FSCV repeated at 60 Hz (Figure 8.3A).  The delay 
time was < 10 ms with amperometry (Figure 8.3A), a process that we have previously 
attributed to diffusion from the release site to the electrode (Venton et al., 2003).  When the 
FSCV time delay was deconvoluted from the dopamine signal, simplex regression of the 
amperometric signal and FSCV data yielded similar Vmax values of 6.01 and 6.06 µM/s 
respectively.  These similarities confirm that at 60 Hz, FSCV is able to effectively model 
dopamine uptake kinetics despite the presence of an adsorptive time delay at the electrode.   
 Ascorbic acid has been shown in improve the sensitivity of an amperometric 
electrode for dopamine (Venton et al., 2003).  The presence of 500 μM ascorbate in the 
aCSF enhanced the signal due to released dopamine from electrical stimulation of brain 
slices by greater than two fold (Figure 8.3B).  It did not significantly alter (p > 0.05) the time 
of peak oxidation or the measured uptake rate of dopamine.  Ascorbic acid was also present 
for the release files taken in Figure 8.3A and allowed for flow cell calibration of the 
amperometry signal as previously described (Venton et al., 2003).   
Anesthetics and Neurotransmitter Release 
 The effect of the common anesthetics, ketamine and urethane, on stimulated 
dopamine and 5-HT release was measured in brain slices.  Bath application of 10 µM 
ketamine does not change stimulated dopamine release in the caudate putamen (p > 0.05, n 
= 5).  In addition, 1 mM urethane is unable to significantly alter stimulated dopamine release 
in the striatum (Figure 8.4A, p > 0.05, n = 5).  A similar trend is seen in stimulated 5-HT  
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Figure 8.3  Amperometric recordings do not exhibit the temporal delay customary of an 
FSCV electrode.  A)  Stimulated dopamine release in a striatal brain slice using FSCV at 60 
Hz and amperometry.  The adsorption of dopamine during FSCV causes a 40 ms delay in 
the rise to the peak [DA] that is not present during amperometry.  A temporal deconvolution 
factor can be used to remove this temporal distortion; the Vmax value reported for the 
deconvoluted FSCV trace is the same as the amperometric trace.  B)  Striatal brain slices 
lack endogenouse ascorbic acid; supplementation of 500 µM ascorbic acid enhances the 
amperometric signal without altering its time course.  
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release in SNr containing brain slices.  Ketamine does not significantly alter (Figure 8.4B, p 
> 0.05, n ≥ 3) 5-HT release in the SNr; furthermore, there was no effect on stimulated 
release by urethane. 
Iontophoretic Ejection Markers and Dopamine Release 
 Several compounds have shown promise as electroactive ejection markers for 
quantifiable iontophoretic drug application (Herr et al., 2008).  Stimulated dopamine release 
in striatal brain slices was measured in the presence of hydroquinone (HQ), 
nitrophenoxyethanol (NPE), and acetamidophenol (AP) to determine any possible effects of 
these compounds.  The ejection marker HQ has a small but insignificant effect on stimulated 
dopamine release (Figure 8.5, p > 0.05, n= 5).  As Figure 8.5 indicates, ejection markers 
NPE and AP reduce stimulated dopamine release by 30 %, a reduction that is significant (p 
< 0.01, n = 5).   
Changes in Basal Dopamine Concentrations 
 AMPH and methamphetamine (METH) are capable of inducing dopamine reverse 
transport, an effect that requires the dopamine transporter (Jones et al., 1998).  Analog 
background subtracted cyclic voltammetry was combined with principal component 
regression analysis to accurately monitor dopamine concentration changes over long time 
periods (~ 40 min.) (Hermans et al., 2008).  Figure 8.6A shows an example CV created 
based on a training set of dopamine CVs taken at the recording site.  PCR was used to 
measure dopamine concentrations in the presence of changes in background current and 
capacitance.  Figure 8.6B shows an average dopamine trace (n = 5, each drug) over 40 min. 
of applied AMPH or METH; for clarity, every 100th data point is shown.  The drug was 
applied (10 µM) at t = 2 min, dopamine efflux began at 5 minutes and achieved 90 % of its 
maximum concentration at 10 minutes (Figure 8.6B).  The maximal dopamine concentration 
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Figure 8.4  Anesthetics used during in vivo experimentation do not cause changes in striatal 
dopamine release or 5-HT release in the SNr.  A) Stimulated dopamine release in striatal 
brain slices is unaffected by 10 µM ketamine application nor 1 mM urethane application (p > 
0.05, t-test, n = 5 both drugs).  B) 5-HT release in brain slices containing the SNr is not 
altered by ketamine nor urethane (p > 0.05, t-test, n ≥ 3 both drugs). 
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Figure 8.5  The effect of iontophoretic marker compounds on dopamine release in striatal 
brain slices.  Three electroactive uncharged markers used to quantify electroosmotic flow 
were applied to striatal brain slices so their effect on stimulated dopamine release could be 
evaluated.  Hyrdoquinone (HQ) at 20 µM had no effect on stimulated dopamine release.  
Nitrophenoxyethanol (NPE) and acetamidophenol (AP) both at 20 µM significantly 
attenuated the dopamine signal (**, p < 0.01, n = 5 each drug). 
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Figure 8.6  Changes in basal dopamine concentration over long time periods can be 
accurately determined using principal component regression (PCR) analysis to remove 
contributions of electrode drift to the analytical signal.  A) Dopamine training set CV used to 
extract a pure dopamine signal from the convoluted current trace.  B) Basal dopamine 
concentration as determined by PCR before and after the application of 10 µM 
amphetamine (AMPH) or methamphetamine (METH) to striatal brain slices, every 100th data 
point shown for clarity.  There are no significant (p > 0.05, n = 5 each drug) differences in 
the reverse transport caused by AMPH vs. METH. 
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achieved by either drug was on average 7.0 µM, almost 4 times higher than the average 
dopamine released upon electrical stimulation in this brain region and similar to that 
reported previously (Jones et al., 1998).  There was no significant difference in either the 
magnitude or rate of dopamine reverse transport between the two drugs (p < 0.05). 
Discussion 
Waveform Application Frequency and Temporal Response 
 Carbon fibers are a desirable sensor surface for dopamine studies because they are 
capable of adsorbing or pre-concentrating dopamine on their surface.  Pre-concentration 
enhances the current signal associated with the dopamine measurement and makes subtle 
changes in dopamine concentration more apparent.  The amount of dopamine that adsorbs 
to the electrode surface can be controlled in part by changing the amount of time the 
electrode is held at a negative potential (- 0.4 V) (Figure 8.1A) (Bath et al., 2000).  
Additionally, modified waveforms can be used to over oxidize the carbon surface and 
increase the electrode’s sensitivity for dopamine (Heien et al., 2003).  A side effect of 
dopamine adsorption to the electrode is the introduction of a time delay in response to rapid 
changes in dopamine concentrations around the electrode (Figure 8.1A) (Bath et al., 2000).  
Recently, a deconvolution procedure was developed to accurately account for and remove 
the temporal delay associated with adsorption (Venton et al., 2002).  Deconvoluted in vivo 
FSCV current traces were shown to be similar to those obtained with constant potential 
amperometry, which does not suffer from an adsorptive time delay (Venton et al., 2002).  
Until recently, this deconvolution procedure was considered sufficient for removal of the 
electrode time delay and accurate measurements of dopamine uptake.   
 Current deconvolution procedures are inadequate for the study of dopamine uptake 
kinetics in striatal brain slices when the adsorptive time delay is too large.  This time delay is 
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reduced by increasing the waveform application frequency from 10 Hz to 60 Hz (Bath et al., 
2000).  Less adsorption improves the temporal response of the electrode to rapid changes 
in dopamine concentration evident by a shorter delay time from stimulation to [DA]max 
(Figure 8.1B).  The time to reach [DA]max for an electrode cycled at 60 Hz is 67 ms instead of 
200 ms at the same electrode cycled at 10 Hz.  The additional delay induced by the 10 Hz 
application frequency decreases the accuracy of the dopamine uptake measurement even 
when the delay of 200 ms has been accounted for by deconvolution.  When both traces are 
fit to Michaelis-Menten kinetics using non-linear regression (Wu et al., 2001), the 10 Hz 
application frequency underestimates Vmax by 22 %.  The underestimation in Vmax is due to a 
reduced electrode sensitivity to fast dopamine dynamics in the brain slice. 
 Slowing dopamine uptake abolishes the measurement penalty due to the increased 
temporal distortion at 10 Hz.  The application of 10 µM cocaine slows the rate of dopamine 
clearance from the extracellular space without changing the electrochemical dynamics of 
dopamine detection (Jones et al., 1995a; Davidson et al., 2000; Uhl and Lin, 2003) (Figure 
8.2A).  As Figure 8.2A shows, the 10 Hz application over estimates the amount of dopamine 
released after the stimulation and indicates that cocaine is having a larger effect on uptake 
when compared to the same electrode cycled at 60 Hz.  This qualitative difference is not 
manifested as an overestimation in Km(app) for a given concentration of cocaine (Figure 8.2B) 
and most likely reflects the reduced sensitivity of the 10 Hz electrode when the uptake rate 
is close to Vmax.  When ascending concentrations of cocaine (1-20 µM) are given and the 
corresponding values of Km(app) are plotted, a value of Ki can be calculated (Jones et al., 
1995a).  Cocaine Ki values calculated in the same location by the same electrode do not 
differ when the electrode is cycled at 60 Hz instead of 10 Hz giving values of 0.32 µM and 
0.30 µM respectively.  The Vmax and Km(app) data suggest that the insufficient uptake 
modeling at 10 Hz is dependent on the rate of uptake.  In cases where uptake is slowed by 
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an inhibitor, both frequencies can used to accurately calculate a Ki for cocaine.  For this 
reason, sampling rates of 10 Hz may still produce valid Vmax values in brain regions where 
dopamine uptake is slower such as the nucleus accumbens (NAc) or basolateral 
amygdaloid nucleus (Jones et al., 1995b).   
Deconvoluted FSCV Mimics Amperometry 
 The question remains: is a 60 Hz application frequency sufficiently fast to make the 
deconvolution procedure described in Venton et al. (2002) valid for uptake measurements in 
striatal brain slices?  When stimulated release is measured and compared using FSCV at 60 
Hz and constant potential amperometry, there is time shift of 40 ms during FSCV that is not 
present during amperometric detection (Figure 8.3A).  The time delay is due primarily to the 
kinetics of adsorption at the electrode and can be completely removed by deconvolution.  
The maximal uptake rate for this location measured by amperometry is the same as that 
taken from simplex modeling of the deconvoluted FSCV signal.  FSCV at 60 Hz has a 
sufficiently small time delay that it can be completely removed by deconvolution and 
accurate uptake measurements made.  The robustness of uptake measurements made by 
FSCV at 60 Hz was also tested using mice that have faster than normal dopamine uptake 
(Chapter 4).  Little difference was found in the Vmax values reported for these animals by 
FSCV and amperometry.  Taken together, these data validate the deconvolution and 
modeling procedures; however, there is a limit to the amount of temporal distortion that can 
be removed using current techniques. 
Amperometry has enhanced time resolution over FSCV; however, the sensitivity and 
calibration of amperometric electrodes remains problematic.  Small currents associated with 
amperometric detection of dopamine in brain slices increase the challenge of using it as a 
primary technique for catecholamine detection.  When performing amperometry in a brain 
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slice, it is necessary to supplement the aCSF buffer with ascorbate at a concentration 
mimicking brain levels so that calibration of the amperometric signal can be made (Rice, 
1999; Venton et al., 2003).  The ascorbic acid creates a catalytic cycle close to electrode 
surface limiting the diffusion layer and enhancing the current response to dopamine 
oxidation (Venton et al., 2003).  As shown in Figure 8.3B, the supplementation of a striatal 
brain slice with 500 µM ascorbate enhances the current signal associated with the release 
and uptake of dopamine without changing its temporal response.  Post calibration of the 
electrode used in Figure 8.3A using FSCV and amperometry in a flow injection system 
yielded the same dopamine concentration.   
Anesthetic Effects on Stimulated Dopamine Release 
A wide range of anesthetic technologies are currently in use for survivable and non-
survivable procedures in animal subjects.  Accordingly, work has been done on the possible 
effects of these anesthetics on neurotransmitter release (Horishita et al., 2008; Rowley and 
Flood, 2008; Tose et al., 2009).  The injectables ketamine and urethane are used in our 
survivable and non-survivable procedures respectively.  Brain slice experiments were done 
to determine if either drug had an appreciable effect on dopamine or 5-HT release.  The 
application of 1 mM urethane to brain slices did not significantly (p > 0.05) alter stimulated 
dopamine release in the caudate putamen or stimulated 5-HT release in the SNr (Figure 8.4 
A and B).  Urethane is widely used anesthetic in rodent preparations because it provides 
deep anesthesia without significant cardiovascular or respiratory depression.  Urethane 
affects a variety of ion channels, including n-methyl-d-aspartate (NMDA) and γ-amino butyric 
acid (GABA) channels both of which are known to regulate dopamine release (Schmidt and 
Fadayel, 1996; Plaznik et al., 1997; Svensson, 2000; Hara and Harris, 2002).  However, 
anesthetic doses of urethane do not change dopamine release or uptake in vivo as 
measured by chronoamperometry (Sabeti et al., 2003).  Our results support the in vivo data 
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by showing that there is no local effect of urethane on stimulated dopamine release.  The 
effects of urethane on 5-HT release are not well documented; however, our data implies the 
lack of an effect. 
Ketamine does not change neurotransmitter release in the caudate or the SNr 
(Figure 8.4 A and B).  It does alter the electrode sensitivity to both neurotransmitters by 30-
35 %; however, Figure 8.4 has been adjusted for the sensitivity reduction revealing no 
ketamine effect on release.  Ketamine is an NMDA receptor (NMDAR) antagonist and has 
been shown to significantly increase the levels of 5-HT and dopamine in vivo and in brain 
slices (Irifune et al., 1991; Lindefors et al., 1997; Tso et al., 2004).  The ketamine effect 
described in the literature indicates that NMDAR activation is inhibitory at dopamine and 5-
HT synapses; however, our data indicates no contribution from NMDARs on stimulated 
release.  The opening of NMDAR channels requires binding of glutamate and the cofactor 
glycine to the receptor followed by membrane depolarization to remove a Mg2+ ion blocking 
the channel (Albensi, 2007).  All three steps are required for channel opening and 
subsequent ion transport (Na+, K+, and Ca2+) into the presynaptic terminal.  The lack of 
glycine and glutamate tone in the brain slice coupled with the presence of Mg2+ in the 
perfusion buffer would keep the NMDAR normally inactivated.  Therefore, any effect by 
released glutamate or glycine (co-released with dopamine by the stimulation) in brain slices 
would occur once when the Mg2+ block was removed by membrane depolarization.  Long 
stimulation trains would be susceptible to the inhibition of release by presynaptic NMDAR 
activation because sufficient time would elapse during the stimulation for receptor 
occupation and channel opening (Fields et al., 2007).  Exactly how NMDARs affect 
dopamine and 5-HT release remains unclear; however, AMPARs may negatively regulate 
striatal dopamine release through H2O2 formation (Avshalumov et al., 2008).  The 
stimulation parameters used in this study (single pulse for dopamine and 20p 100 Hz for 5-
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HT) are too brief to effectively probe the action of NMDARs on release.  For example, 
dopamine release evoked by a single pulse electrical stimulation is devoid of autoreceptor 
effects which also regulate release by acting on presynaptic terminals (Kennedy et al., 
1992).  We conclude that the NMDAR is normally blocked in brain slices containing the 
caudate putamen or SNr, and that the release evoked by our stimulation parameters is not 
affected by activation of the NMDAR because the time course is too short.   
Iontophoresis Markers and Dopamine Release 
 Several electroactive substances have been identified as markers to be used with 
iontophoretic ejections.  The marker HQ did not alter stimulated dopamine release in striatal 
brain slices (Figure 8.5); however, both NPE and AP significantly decreased stimulated 
dopamine released (Figure 8.5).  None of the compounds shown in Figure 8.5 appreciably 
altered the sensitivity of the electrode for dopamine when tested in a flow injection 
apparatus.  The reduction of dopamine by AP is supported by Fiebich et al. (2006) who 
found striatal dopamine release to be diminished in slices incubated with a mixture of 
aspirin, caffeine, and acetaminophen (Fiebich et al., 2006).  There is no evidence from the 
literature to support or refute the release effects of HQ or NPE.  This work is the first 
documented case of NPE decreasing stimulated striatal dopamine release in brain slices. 
Dopamine Reverse Transport 
 The action of AMPH on basal dopamine levels in striatal brain slices was previously 
evaluated using FSCV and found to require the presence of DAT (Jones et al., 1998).  In 
that study, the current due to oxidation of dopamine was separated from the background 
current in a different manner than is typically used for short stimulations.  For those 
measurements, the background current measured with AMPH present was subtracted by a 
single background taken without AMPH present; the difference in these backgrounds was 
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taken as the current due to dopamine concentration changes around the electrode.  This 
approach is valid if the only parameter changing over the files being subtracted is dopamine.  
Over the timeframe of reverse transport (10-40 min.), the inherent instability of the electrode 
causes changes in the background that are not due to changes in dopamine concentration 
(Hermans et al., 2008).  As a result, the cyclic voltammograms used to identify dopamine 
are less reliable with subsequent files that are further removed in time from the original 
background file.  PCR is able to account for components of the background not related to 
dopamine and remove them from the signal (Heien et al., 2004; Hermans et al., 2008).  The 
data shown in Figure 8.6B is an example of a pure dopamine trace in which background 
components other than dopamine have been removed by PCR.  Therefore, Figure 8.6B only 
shows current that arises from changes in the dopamine concentrations.  PCR increases the 
level of certainty that the measured changes are due only to dopamine. 
Analog background subtraction and PCR were used to elucidate if the structural 
differences between AMPH and METH affected their ability to induce reverse transport.  
AMPH and METH differ in structure only by the presence of a methyl group and have similar 
mechanisms of action: they both block the DAT, inhibit VMAT2, and cause reverse transport 
of cytosolic dopamine (Sulzer et al., 2005).  However, their addictive properties are thought 
to be much different with METH being more addictive than AMPH.  Figure 8.6B clearly 
shows that there is no significant (p > 0.05) difference in the rise time or [DA]max achieved by 
either drug when VMAT2 is first inhibited with tetrabenazine; therefore, the reverse transport 
of dopamine caused by these drugs is not different.  It is possible that the increased 
hydrophobicity of METH allows it to more easily cross the plasma membrane.  Greater 
METH accumulation presynaptically would enhance VMAT2 inhibition and cause greater 
reverse transport, a mechanism not probed in the slice experiment.  However, in vitro work 
in isolated cells showed no difference in the amount of dopamine released by AMPH vs. 
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METH (Goodwin et al., 2009) and in vivo microdialysis data showed dopamine increases 
due to METH and AMPH in the NAc are the same (Shoblock et al., 2003).  In conclusion, 
the addictive nature of the AMPH stimulants is not due solely to their action at the 
monoamine transporter and are more likely the result of global changes in brain circuitry 
(Kalivas, 2007).   
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